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Abstract 
Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several 
FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma 
patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treat-
ment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impres-
sive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, 
now exceeding 80%. Can we improve response rates even further, and bring these therapies to more patients? In fact, 
despite these advances, responses are heterogeneous and are not always durable. There is a critical need to better 
understand who will benefit from therapy, as well as proper timing, sequence and combination of different therapeu-
tic agents. How can we better understand responses to therapy and optimize treatment regimens? The key to better 
understanding therapy and to optimizing responses is with insights gained from responses to targeted therapy and 
immunotherapy through translational research in human samples. Combination therapies including chemotherapy, 
radiotherapy, targeted therapy, electrochemotherapy with immunotherapy agents such as Immune Checkpoint 
Blockers are under investigation but there is much room for improvement. Adoptive T cell therapy including tumor 
infiltrating lymphocytes and chimeric antigen receptor modified T cells therapy is also efficacious in metastatic mela-
noma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T 
cells. Tumor infiltrating lymphocytes therapy is also efficacious in metastatic melanoma and outcome enhancement 
seem likely by improved homing capacity of chemokine receptor transduced T cells. Understanding the mechanisms 
behind the development of acquired resistance and tests for biomarkers for treatment decisions are also under study 
and will offer new opportunities for more efficient combination therapies. Knowledge of immunologic features of 
the tumor microenvironment associated with response and resistance will improve the identification of patients who 
will derive the most benefit from monotherapy and might reveal additional immunologic determinants that could be 
targeted in combination with checkpoint blockade. The future of advanced melanoma needs to involve education 
and trials, biobanks with a focus on primary tumors, bioinformatics and empowerment of patients and clinicians.
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Evolving topics in cancer immunotherapy
Radiotherapy and immunotherapy
The first evidence that T cells contribute to the local (and 
possibly systemic) response to tumor-targeted radio-
therapy (RT) was published over 30  years ago [1], but 
as only recently it was demonstrated in pre-clinical can-
cer models that the abscopal effect (i.e., tumor regres-
sion outside of the field of radiation following RT to one 
lesion) is immune-mediated [2]. Progress in understand-
ing the complex molecular mechanisms that regulate 
T cell activation, migration to tumor site and effector 
functions within tumors has led to the identification of 
several mechanisms that prevent immune-mediated 
tumor rejection in most patients. Some of these mecha-
nisms have been successfully targeted therapeutically by 
using antibodies blocking inhibitory immune checkpoint 
receptors such as cytotoxic T-lymphocyte associated 
protein 4 (CTLA-4) (e.g., ipilimumab) and programmed 
death 1 (PD-1) (e.g., nivolumab, pembrolizumab, atezoli-
zumab) [3].
However, most patients do not respond to single agent’s 
therapy with immune checkpoint blockers (ICB). In this 
context, RT has been demonstrated to be a good combi-
nation partner for ICBs that increases responses against 
poorly immunogenic tumors in mice [4], and sometimes 
in patients [5, 6]. Proof-of-principle studies have demon-
strated that RT can contribute at three levels to immune-
mediated tumor rejection: (1) by generating anti-tumor T 
cells; (2) by overcoming T cell exclusion from the tumor; 
(3) by enhancing T cell-mediated recognition and kill-
ing of cancer cells that survive RT [7]. Thus, RT is under 
investigation as a modifier of the tumor microenviron-
ment shifting so called “cold” tumors, which lack immune 
infiltrate (refractory to ICB), to so called “hot” tumors 
with lymphocyte infiltrate present (responsive to ICB).
Despite this experimental evidence, the promise of 
RT to convert the irradiated tumor into an in  situ vac-
cine and elicit systemic anti-tumor immune responses 
capable of mediating abscopal effects (i.e., regression 
of metastases outside of the field of radiation) remains 
elusive. A number of active clinical trials combining RT 
with ICBs are ongoing: 18 trials testing radiotherapy with 
anti-CTLA-4, 51 trials testing radiotherapy with anti-
PD-1/PD-L1, with radiotherapy regimens varying from 
1.8 GyX28, to 3 GyX10, to stereotactic radiosurgery with 
single doses of 20 Gy or more [8].
Our group has investigated the impact of RT dose and 
fractionation on the ability of RT to synergize with ICBs 
and induce abscopal effects. We found that a hypofrac-
tionated regimen of 8GyX3 was effective while a single 
dose of 20 Gy was not [9]. In addition, we recently identi-
fied the mechanism underlying this difference in immu-
nogenicity of different RT regimens. Hypo-fractionated 
RT induces cancer cell-intrinsic Interferon type I (IFN-
I) pathway activation and production of IFNβ, which is 
required for optimal recruitment to the tumor of BATF3-
dependent dendritic cells. Cancer cell expression of the 
cytoplasmic DNA sensor cGAS and its adaptor STING 
are required for RT-induced IFN-I production. Induc-
ible knockdown of cGAS or STING in the irradiated 
tumor abrogated the induction of anti-tumor CD8 T cells 
by 8GyX3 RT and CTLA-4 blockade, and abolished the 
occurrence of abscopal effects. Finally, since cGAS is a 
sensor for double-stranded (ds) DNA, we investigated its 
presence in the cytoplasmic fraction of cancer cells irra-
diated with 8GyX3 or 20 Gy. These experiments revealed 
that RT induces the accumulation of dsDNA only in can-
cer cells treated with 8GyX3 but not 20 Gy [10]. In con-
clusion, the radiation dose and fractionation is a critical 
determinant of RT synergy with ICBs. Stimulation of 
cancer cell-intrinsic IFNβ production by RT is required 
to prime anti-tumor CD8 T cells to poorly immunogenic 
tumors. These findings have important implications for 
the choice of RT dose and fractionation when used in 
combination with ICBs.
Immunocytokines (ICs) are a class of molecules cre-
ated by linking tumor-reactive monoclonal antibodies 
(mAbs) to cytokines that are able to activate immune 
cells. Tumor selective localization is provided by the abil-
ity of the mAb component to bind to molecules found on 
the tumor cell surface and molecules found selectively in 
the tumor microenvironment. In this way, the cytokine 
component of the immunocytokine is selectively local-
ized to sites of the tumor and can activate immune cells 
with appropriate receptors for the cytokine.
It has been previously shown that an intratumoral 
(IT) injection of IC, which consists of an antitumor Ab 
specific to disialoganglioside (GD2) linked to interleu-
kin (IL)-2, can serve as an in  situ vaccine. It enhances 
local antitumor effects and can generate an adaptive 
T cell response directed against distant tumors. These 
in situ vaccine effects involve T cells as well as NK cells, 
and can result in T cell memory in melanoma and neu-
roblastoma (NBL) as demonstrated in preclinical stud-
ies. Preclinical studies have shown that tumor-reactive 
mAbs can mediate in  vitro tumor destruction via anti-
body-dependent cellular cytotoxicity (ADCC). Based 
on these results clinical approach was developed at the 
Children’s Oncology Group (COG) administering this 
agent in individuals with smaller burden of cancer (non-
bulky disease) [11]. This approach was tested clinically in 
the minimal disease setting in a pilot COG phase 1 trial 
for children with high risk NBL that were in remission 
after autologous hematopoietic stem cell transplantation 
(HSCT) (ASCT) but likely to relapse. To augment ADCC 
cytokines such as IL-2 to activate natural killer (NK) cells 
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and granulocyte–macrophage colony stimulating fac-
tor (GM-CSF) to activate neutrophils/macrophages were 
incorporated. When this same regimen was moved into a 
large COG phase 3 trial with immunotherapy the treat-
ment was statistically superior to the control treatment 
for both event-free survival (66% vs. 46% p = 0.01), and 
for overall survival (86% vs. 75% p  =  0.02). These data 
suggest that other ADCC-mediating mAbs (i.e., rituxi-
mab, herceptin and erbitux) might be considered for tri-
als in which high risk patients likely to relapse receive 
these mAbs in combination with agents known to acti-
vate ADCC (e.g., IL-2 + GM-CSF).
Because the efficacy of anti-GD2 mAb +  cytokines in 
NBL trial was only 66% and NBL-free survival at 2 years 
further enhancement of the clinical potency of ADCC to 
obtain even better clinical results was undertaken [11]. 
The ICs were constructed by fusing the human IL-2 gene 
to the chimeric (ch) 14.18 or humanized (hu) 14.18 IgG1 
genes to activate IL-2 receptor positive (IL-2R+) effec-
tor cells with a molecule that bridges them to tumor cells 
and then activates them. Indeed it was shown that these 
ICs activate GD2-specific tumor cell binding by IL-2R+ 
T cells and NK cells [11]. Ch14.18-IL-2 induces anti-mel-
anoma activity in a SCID-xenograft model and in con-
ventional mice bearing syngeneic tumors expressing GD2 
(B78 melanoma); and anti-NBL activity in conventional 
mice bearing the GD2+ NXS2 NBL [11]. However, when 
IC (hu14.18-IL-2) was used clinically, anti-tumor activity 
is accompanied by dose-limiting IL-2-related toxicities 
suggesting the need to design the reagents and mouse 
models that better simulate the potential activity of IL-
2-based on in vivo immunotherapy in patients [12].
As a single-agent immunotherapeutic approaches can 
have limited efficacy, combining two or more immu-
notherapeutic strategies can be synergistic in induc-
ing antitumor effects. There is a growing enthusiasm 
for testing checkpoint blockade in combination with 
other approaches to augment immune-mediated anti-
tumor effects. Recently synergistic effect of the combi-
nation of anti-CTLA-4 mAb blockage and intratumor 
(IT) administration of the IC on smaller tumors (day-7 
B78,  <  50  mm3) was demonstrated although the treat-
ment was less efficacious on larger tumors (day 12, B78 
tumors) [13]. Recent studies of mAb/cytokine-based 
immunotherapies for solid tumors have shown IT-IC is 
more effective for measurable mouse tumors [13, 14] and 
that IV treatment (mAb or IC) can be effective in mini-
mal residual disease (MRD) setting (COG studies) [15].
However, combination with immunomodulatory, 
radiation and IT hu14.18-IL-2 administration results in 
cure of most large tumors (5-week, 200 mm3, B78) [14]. 
Results show that combining RT and IT-IC in murine 
tumor models can eradicate large tumors and metastases. 
This suggests that in  situ vaccination effect can be 
enhanced by T cell checkpoint blockade, with implica-
tions for clinical evaluation. Preclinical data demonstrate 
that IT-IC + RT (and anti-CTLA-4) activates innate and 
adaptive immunity, overcomes tumor induced immune 
suppression, and facilitates use of existing tumors as 
in situ vaccines.
The following data support the strategy of increasing 
the efficacy of the IC vaccine via IT delivery: (1) IT-IC 
causes much higher levels of IC in the injected tumor 
than IV-IC; (2) Greater IC levels in the tumor enhance 
NK infiltration into the tumor (via FcRs and IL-2Rs), 
leading to greater ADCC and greater tumor destruction, 
even of larger macroscopic lesions that are unresponsive 
to IV IC delivery; (3) Some of the IC injected IT circu-
lates systemically (via lymphatics and blood vessels), ena-
bling IC delivery to distant sites as effectively as when IC 
is given IV (possibly with a better PK profile); (4) The IC-
facilitated response within the tumor may attract other 
effector cells (T cells and macrophages) to the tumor 
site (or to draining lymph nodes), leading to T cell sen-
sitization; (5) The vaccine-like effect resulting in tumor-
specific T cell reactivity may impact on distant sites of 
micrometastatic disease (and prevent subsequent growth 
upon experimental tumor re-challenge); and (6) Combin-
ing IC with other treatments that cause localized tumor 
damage (without local immune suppression), should syn-
ergistically augment the antitumor activity of the IC.
Cancer vaccines in the era of checkpoint blockade
A cancer vaccine is a preparation of a tumor antigen 
that upon administration stimulates antibody produc-
tion or cellular anti-tumor immunity. In fact, it is known 
that T cells can mediate remarkable tumor regressions 
including complete cure in patients with metastatic can-
cer. The mutanome, the collective genetic alterations in 
an individual’s cancer cells, encodes peptides (M-pep-
tides) that can function as unique therapeutic targets as 
neoantigens.
M-peptides in individual patients can be identified by 
next-generation sequencing and computational algo-
rithms guided approaches for T cell epitope prediction. 
Although there is a correlation between peptide bind-
ing affinity for MHC class I and II and immunogenic-
ity, other factors also contribute. For example, sufficient 
affinity of the interaction between MHC-bound mutated 
peptide and the T-cell receptor (TCR) is essential for the 
recognition of the mutated peptide as ‘foreign’. The iden-
tification of epitopes that drive the immune response in 
cancer is essential to the understanding and manipula-
tion of CD8 T-cell immune responses for clinical benefit. 
Recent studies in mice and humans have suggested that 
tumor-specific mutations may have a key role in shaping 
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the anti-tumor response; but their identification remains 
a challenge [16]. To be fully useful in the clinic, it will be 
necessary to rely on computational predictions, including 
structural features of the MHC I-haplotype-specific and 
whole-exome/transcriptome sequencing of a patient’s 
tumor, which is beginning to be routinely determined.
In 2011, Schwartzentruber et al. found that combining 
a melanoma vaccine with IL-2 [high-dose IL-2 ± gp100 
peptide in incomplete freund adjuvant (IFA), i.e., water-
in-oil emulsion], improved the response rate and progres-
sion-free survival in patients with advanced melanoma, 
versus IL-2 alone [17]. Currently there are 369 open stud-
ies using cancer vaccines in the USA only, most with lit-
tle or no evidence of tumor regression. Limited tumor 
regression following treatment with vaccines could also 
be due to immunosuppressive tumor microenvironment 
even in the presence of increased frequency of cancer-
specific T cells. These T cells in the tumor microenvi-
ronment are likely those that are not proinflammatory, 
or with poor T cell effector function/wrong phenotype. 
Other tumor phenotypes that account for most of nonre-
sponders are due to few T cells or poor T cell trafficking 
to tumor. Insufficient spontaneous T cell reactivity and/
or lacking immune cell infiltration to tumor site could be 
one of the limitations of effective anti-tumor response 
[18]. Such tumor-specific T cell responses could be 
induced through anti-cancer vaccination, but despite 
great success in animal models, only a few of many cancer 
vaccine trials have demonstrated robust clinical benefit.
As vaccine adjuvants determine the type and magni-
tude of the T cell response after vaccination one possible 
explanation for the lack of efficacy of vaccine therapy in 
humans is the use of safe, but very weak vaccine adju-
vants in clinical trials as opposed to the use of potent, 
effective vaccine adjuvants in animal models [18]. Vac-
cine adjuvants for peptide-based cancer vaccines can 
function as an antigen depot for prolonged release, can 
protect antigen from degradation, can increase antigen 
uptake by antigen presenting cells (APCs) or can induce a 
pro-inflammatory/pro-immunogenic milieu.
Persisting peptide/IFA vaccine depots can induce spe-
cific T cell sequestration, dysfunction and deletion at 
vaccination sites, possibly explaining lack of synergy 
between gp100 peptide vaccination and ipilimumab in 
patients with melanoma [19]. On the contrary, short-
lived formulations can overcome these limitations and 
result in greater therapeutic efficacy of peptide-based 
cancer vaccines [20].
Recently, Hailemichael et  al. demonstrated that IFA-
based vaccination does not synergize with anti-CTLA-4 
therapy and that IFA-based vaccination sequesters T 
cells induced by anti-CTLA-4 therapy. More promising 
results were obtained from virus-based vaccination that 
synergizes with anti-CTLA-4 therapy and water-based 
peptide vaccination that synergizes with anti-PD-1 ther-
apy (Hailemichael et  al., in press). Given that the adju-
vant choice determines T cell response to cancer vaccine, 
molecular adjuvants like TLR agonist, CD40 agonists or 
cytokine are investigated.
IT immunotherapy can be an alternative to inefficient 
systemic cancer vaccines. Such therapy could empower 
the immune system to mount T cell responses against 
various immunogenic tumor-associated antigens. To 
mediate systemic tumor regression, intratumoral (IT) 
immunotherapy must generate systemic T cell responses 
that can target distant metastases beyond the initially 
treated tumor mass [21].
Intratumoral (IT) treatment with 3M-052 (an inject-
able, tissue-retained TLR 7/8 agonist) was found to be 
a promising approach for the treatment of cancer thus 
establishing a rational strategy for combination therapy 
with IT, tissue-retained TLR7/8 agonist and checkpoint 
blockade in metastatic cancer [22]. IT administration of 
3M-052 generated systemic antitumor immunity, and 
sensitized both injected an uninjected wild-type B16.F10 
melanomas to checkpoint blockade therapy with anti-
CTLA-4 and anti-PD-L1 antibodies, even when check-
point blockade alone was ineffective [22].
In conclusion, cancer vaccines can have clinical impact 
by synergizing with checkpoint blockade. To induce bet-
ter T cell responses and clinical impact, relevant factors 
are formulation (linked to possible T cell sequestration), 
addition of multiple immunomodulators (cytokines, TLR 
agonists), combination with checkpoint blockade and 
use of intratumoral immunotherapy as a vaccine strategy 
need to be considered.
Tumor infiltrating lymphocytes (TIL) therapy in melanoma
Adoptive T cell therapy (ACT) with autologous tumor 
infiltrating lymphocytes (TILs) is an effective treatment 
for patients with metastatic melanoma. TILs that are 
expanded in  vitro, and reinfused in conjunction with 
IL-2 following a lymphodepletion has been a method 
for treatment of heavily pretreated cancer patients [23]. 
ATC treatment shows objective responses in about 
50% of patients in clinical trials, with a 20% of complete 
responses. TILs are mainly CD T-cell-based cultures and 
better quality of TILs are associated with better clinical 
outcomes including overall survival. Higher T cell infil-
trate in tumors could be accomplished by vaccination, 
target therapy (e.g., BRAF) and the exercise.
However, TIL therapy infusion products lack strong 
predictive markers and the limitation of the optimal 
responses include inability of T cells to infiltrate the 
tumor site, immunosuppressive environment, and the 
quality and quantity of TILs. Efforts are ongoing to 
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generate more potent TILs or to improve intratumoral 
infiltration in patients including co-stimulation through 
the 4-1BB/CD137 antibody which increases the CD8+ T 
cells frequency. The use of K562− derived artificial anti-
gen presenting cells (APCs), which act as a feeder cells 
for T-lymphocytes expansion is also used. Among meth-
ods to improve adoptive T-cell therapy, the administra-
tion of checkpoint inhibitory antibodies activating T cells 
or depletion of myeloid derived suppressor cells (MDSC) 
to reduce immunosuppression are proposed. Another 
method is re-stimulation of the injected TILs with a 
tumor vaccine to improve life-span of the antigen specific 
T cells. Other strategies to counterbalance tumor-driven 
immune dysfunction are reversing the oxidative stress in 
cancer patients by the administration of histamine and 
antioxidants (e.g., vitamin E).
Exercise can exert a great anticancer effect [24–26]. 
Regular exercise delay progression and growth of tumors 
in numerous experimental models [27, 28]. Furthermore, 
therapeutic effect of exercise on cancer is demonstrated 
in cancer patients, for example decreased tumor progres-
sion in prostate cancer [26]. Multiple studies (n  =  88) 
reported on associations between physical activity after 
diagnosis and prognosis among cancer survivors showing 
an impact of exercise on cancer survival. Unfortunately, 
there are differences in the models and the type of physi-
cal intervention which make difficult comparisons with 
cancer survival. Mechanism(s) for the effect of physical 
activity in cancer remain unknown although dietary and 
hormonal factors have been postulated (e.g., insulin and 
insulin-like growth factor, inflammatory markers).
Recent findings demonstrated that voluntary wheel 
running significantly reduces tumor incidence and 
growth in various experimental tumor models [29]. 
Exercise, cancer, and immunity are linked as exercise 
decreases tumor incidence and growth by over 60% 
across several mouse tumor models. Exercise control of 
tumor growth is mediated through a direct regulation of 
NK cell mobilization and trafficking. Mechanisms involve 
epinephrine-dependent mobilization of NK cells to the 
circulation and IL-6-dependent redistribution to the 
tumors. In particular, exercise increases NK cell infiltra-
tion into tumor site, thereby controlling tumor growth. 
Epinephrine mobilizes NK cells and blunts the tumor 
suppression. In addition, exercise-induced muscle-
derived IL-6 is involved in NK cell redistribution [29]. 
For example, subcutaneous B16F10 melanoma model in 
female mice demonstrated that 4 weeks of wheel running 
prior to tumor cell inoculation reduced tumor growth 
by 61% (p  <  0.01). These findings indicate that exercise 
might deliver a therapeutic effect with increased immune 
cell infiltration and generation of an inflammatory intra-
tumoral environment [29].
In conclusion, exercise, may lead to mobilization and 
tumor infiltration of T and NK cells animal models. 
Although the mechanism of increase in physical activ-
ity on survival and recurrence in cancer patients are 
not established as the randomized controlled trials are 
needed to generate definite data. However, it can have 
positive impact on efficacy of immune therapy, includ-
ing ACT such as TILs or other types of ACT (e.g., CARs, 
genetically modified T cells etc.) as demonstrated in ani-
mal models.
System biology session: molecular
MicroRNAs and drug resistance to melanoma
Drug resistance is major issue in medical oncology 
because its development limits the long-term efficacy of 
current cancer therapies. Understanding the mechanisms 
behind the development of acquired resistance will offer 
new opportunities for more efficient combination thera-
pies. Some concepts have been demonstrated.
Melanoma patients bearing BRAF V600 mutation ben-
efit from therapy with BRAF inhibitors [30]. Short term 
(6  months) benefit of BRAFi therapy was demonstrated 
[31]. A major issue in the treatment of BRAF mutated 
metastatic melanoma is the disease relapse caused by 
emergence of drug resistance. In most cases BRAFi 
resistant melanoma bear mutations or molecular aber-
rations reactivating the MAPK pathway [32]. Frequent 
reactivation of MEK in BRAFi resistant tumors led to the 
development of BRAFi +  MEKi combination therapies. 
Combination therapy with BRAF and MEK inhibitors 
improves survival but is unable to prevent disease relapse 
[33]. In tumors resistant to BRAFi + MEKi dual therapy 
the same type mutations are found. Therefore, hitting 
hard two different targets in the same pathway doesn’t 
solve the problem and the identification of additional 
mechanisms responsible for drug resistance is an unmet 
need.
In a significant percent of cases (26%) no new muta-
tions that constitute the basis of resistance could be iden-
tified. Other types of molecular changes than mutations 
as adaptive mechanisms can contribute to drug resistance 
in melanoma [34, 35]. MicroRNAs that are important 
multifunctional post-transcriptional modulators of gene 
expression affect multitude of cellular pathways. Micro-
RNAs also play a key-role in various progression-related 
and invasive properties of human cancers. In addition, 
there is a growing evidences suggesting miRNAs as key 
factors controlling the emergence of drug resistance [36]. 
MicroRNAs (miRNAs) are small noncoding RNAs that 
modulate gene expression by mRNA silencing or degra-
dation, which usually have pleiotropic effects because of 
their ability to target simultaneously multiple mRNAs. 
The first example of a miRNA-dependent mechanism of 
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drug resistance in BRAF mutated melanoma focused on 
a previously poorly characterized miRNA, miR-579-3p. 
Main findings were: (1) low expression of miR-579-3p is 
a negative prognostic factor correlating with poor sur-
vival; (2) expression levels of miR-579-3p decrease dur-
ing melanoma progression i.e., from nevi to stage III/
IV melanoma; (3) miR-579-3p acts as oncosuppressor 
by targeting the 3′ untranslated region (3′UTR) of two 
oncoproteins (BRAF and an E3 ubiquitin protein ligase, 
MDM2); (4) moreover miR-579-3p ectopic expression 
impairs the establishment of drug resistance in human 
melanoma cells; and (5) miR-579-3p is strongly down-
regulated in matched tumor samples from patients before 
and after the development of resistance to targeted thera-
pies [37] and was also identified in cell lines resistant to 
BRAF/MEK inhibitors.
Recently, the assessment of changes in the whole miR-
NAome profile during the development of drug resist-
ance in vitro in two different BRAF-mutated melanoma 
cell lines was performed by the Nanostring™ platform 
(Fattore et  al., unpublished). Data revealed a stepwise 
deregulation of a growing number of miRNAs. Deregu-
lated miRNAs of resistant melanoma cells mostly impact 
on pro-inflammatory and pro-angiogenetic pathways. 
Besides, conditioned medium from drug resistant 
WM266 cells triggers directional cell migration, pro-
motes angiogenesis, and its effect is fully inhibited by 
VEGF antagonists (Fattore et al. unpublished). Per other 
findings, anti-PD-1 resistant tumors display a transcrip-
tional signature (IPRES) resembling that of MAPK-resist-
ant melanomas which is at the basis of cross-resistance. If 
a similar network of miRNAs contributes to cross-resist-
ance between MAPKi and checkpoint inhibitors is still to 
be investigated.
Melanoma mutations and ‘precision medicine’
The notion of “precision medicine” is to include molec-
ular markers based on information derived from 
genetics, epigenetics, gene expression and proteom-
ics data to diagnose and treat patients. This subject 
is not new as reflected by over 900 publications since 
2009. Indeed, several institutions already searched for 
a panel of “actionable” mutations (in addition to BRAF 
and NRAS), for targeted therapy. These include MSK-
IMPACT, FoundationOne, and IBM Watson Genomics. 
Ideally, NextGen Sequencing will be used in the near 
future to distinguish primary melanomas from benign 
nevi, to identify tumor heterogeneity, new targets for 
therapy, interactions of tumor cells with the microen-
vironment, the presence of neoantigens, and to moni-
tor tumor load, just to name a few. However, the main 
obstacles to achieve these goals are speed of getting the 
results and the high cost of the tests. One way to alleviate 
the problem is the use MelArray (Melanoma Targeted 
Sequencing) designed by Dr. Michael Krauthammer from 
Yale University in collaboration with Dummer Reinhard 
and Levesque at Dermatology, University of Zurich. This 
array is composed of 190 melanoma mutant genes, TERT 
promoter, and 28 introns across eight genes to identify 
fusion genes such as BRAF, RAF1, ALK, MAP3K8, MET, 
NTRK1, PRKAR1A, and ROS1. The array has reasonable 
sequencing costs; currently about five time lower than 
whole exome sequencing.
A group of investigators at Yale University tested the 
MelArray on several tumors and identified the criti-
cal mutations and genomic aberrations. An interesting 
case was the discovery of the molecular basis of tumor 
heterogeneity in one patient. The four portions of the 
tumor, all isolated at the same time, displayed  NRASQ61R, 
 IDH1R132C,  DDX3XP274L,  ASPMR1763K and TERT 5′Flank 
SNV, but were different in CTNNB1 mutations. We iden-
tified  CTNNB1S45Y,  CTNNB1S45*, and wild-type gene in 
two other sites. Interestingly, the DDX3X, (DEAD-box 
helicase 3, X-linked) might render the tumor susceptible 
to RK-33 [38]. However, it is likely that we need to con-
tinue performing WES to find out the total number of 
mutations and the neoantigens.
Other discoveries are fusion genes in wild type 
BRAF and NRAS melanomas, which include PDE8A-
RAF1, PDE4DIP-BRAF and NFIA-BRAF. We dem-
onstrated that PDE8A-RAF1 is a transforming gene 
that activates the MAPK and confers growth factor 
independence in mouse melanocytes. Melanoma cells 
with PDE8A-RAF1 or PDE4DIP-BRAF were resist-
ant to vemurafenib but highly sensitive to selumetinib 
and SCH772984 (ATP independent MEK1, 2 and ERK 
inhibitors, respectively).
Because molecular analyses generate massive amounts 
of data, there is a need to partner with computational 
biology cores. For example, converting the variant call 
format (VCF) to actual mutations can be a long pro-
cess. We tested the IBM Watson Genomics supports and 
received within minutes the genetic alterations of the 
tumor as well as options for targeted therapy.
In addition to mutations and genomic aberrations, we 
need to analyze gene expression that can help in pre-
dicting response to therapy, especially immunotherapy. 
RNA sequencing of bulk tumors can provide information 
regarding the composition of TIL subsets in the tumor 
microenvironment including IFNγ and IFN pathway 
genes, neoantigen load, and expression of PD-L1 in the 
tumor tissue and micro-environment. Several programs 
were developed to profile leukocyte composition directly 
from RNA sequencing data, and one of them is CIBER-
SORT (cell type identification by estimating relative sub-
sets of known RNA Transcripts) [39].
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In conclusion, a list of ‘omics’ and functional screening 
test should include but is not limited to:
1. Next generation sequencing (NGS): routine analy-
sis of the molecular changes in the tumor(s) in each 
patient; provides therapy targets and biomarkers as 
well as biological input.
2. RNAseq: TILs to be profiled with increasingly high 
resolution and accuracy directly from RNA mixtures 
of bulk tumor samples.
3. Non-invasive test, such as CAPP-Seq (cancer per-
sonalized profiling by deep sequencing of circulating 
tumor DNA) [40].
4. Proteomics analyses in tissue and blood.
5. Functional studies, in vitro and in vivo drug response 
to determine the effects of genomic alterations.
Biomarkers for treatment decisions
Biomarkers have opened the paradigm of ‘precision med-
icine’ by incorporating biomarkers for risk assessment 
and screening (prognostic); at diagnosis, when markers 
can assist with staging, grading (diagnostic), and therapy 
selection (predictive of response); and to select additional 
therapy or monitor for recurrent disease in clinical man-
agement of cancer patients.
Biomarkers such as mutations (NRAS, c-Kit, BRAF) 
are already critical for proper management of advanced 
melanoma patients. Based on the recent data of anti-
PD-1 treatment efficacy in PD-L1-positive advanced mel-
anoma, PD-L1 expression may reflect the presence of T 
cells secreting IFNγ in the tumor microenvironment [41]. 
PD-L1 expression in tumors correlates with the pres-
ence of TILs, since IFNγ production by TILs can induce 
expression of PD-L1. Therefore, this category of tumors 
is likely to respond to TIL targeted therapy unlike tumors 
who do not have T cell infiltrate.
Treatment of systemic metastatic disease (stage IV) 
involves new therapeutic strategies. Immunotherapy, 
that utilizes antibodies that bind to checkpoint inhibi-
tory receptor of T-cells such as CTLA-4 blocking agent 
ipilimumab; the anti-PD-1 antibodies, such as nivolumab 
and pembrolizumab have already demonstrated impres-
sive efficacy [41]. Targeted therapy agents such as selec-
tive BRAF inhibitors including vemurafenib, encorafenib 
and dabrafenib used alone and/or in combination with 
MEK inhibitors such as binimetinib, cobimetinib and 
trametinib, have also demonstrated impressive antitumor 
activity. Therefore, immunotherapy and kinase inhibi-
tors have become the backbone of systemic therapy in 
melanoma.
The field of genetics has made advances in recent 
years and methods to deliver and share genomic infor-
mation for clinical care across different tumor types 
become available. For example, the Foundation of Medi-
cine T5 Gene Panel allows Targeted DNA Sequencing of 
300 genes across all four classes of genomic alterations 
to help understand the genomic makeup of a patient’s 
tumor. In this assay, next-generation sequencing (NGS) 
is used to analyze cancer specimens for all four classes 
of genomic alterations (base substitutions, insertions 
and deletions, copy number alterations, and rearrange-
ments). The targeted sequencing focuses on annotated 
and actionable mutational findings. In addition, high 
sequencing depth also overcomes contamination with 
normal tissue and allows for the detection of mutations 
at subclonal level. Genomic profile analysis using T5 
Gene Panel demonstrated that the frequency of genetic 
alterations of CDKN2A and CDKN2B pathway corre-
lated with short (<  3.5  months) and longer progression 
free survival (PFS) in melanoma patients. This cell cycle 
pathway was frequently altered and it is driven primar-
ily by CDKN2A alterations. As far as HGF/MET altera-
tions are concerned several patients had amplification 
of genes on the 7q chromosome. These patients tended 
to have a shorter PFS than the BRAF-mutant population 
and seven patients exhibited MET (n =  4) and/or HGF 
(n = 6) amplifications, with co-amplification occurring in 
3 of 6 patients. PFS was < 3.5 months for 3 of 4 patients 
with the MET amplification and 5 of 6 patients with the 
HGF amplification (van Herpen et al., submitted).
Furthermore, HGF expression may contribute to thera-
peutic resistance in BRAF-mutant melanoma. A recent 
study in patients with BRAF-mutant melanoma reported 
correlation between HGF expression by stromal cells and 
innate resistance to BRAF inhibitor treatment. Response 
to treatment (BRAFi ± MEKi) was significantly lower in 
patients with stromal HGF expression than in patients 
without HGF expression (p < 0.05) [42]. Treatment with 
a BRAF inhibitor increased stromal HGF expression 
in several patients. Besides, in BRAF-mutant cell lines 
treated with a BRAFi and HGF, HGF induced sustained 
activation of ERK and AKT, which was more pronounced 
under BRAF inhibition than under MEK inhibition. 
These results suggest that genetic alterations leading to 
dysregulation of the MAPK pathway (e.g., HGF amplifi-
cation) could contribute to resistance to BRAFi therapy 
in patients with BRAF-mutant melanoma [42]. These 
data support hypothesis that stromal cells might confer 
innate resistance on cancer cells and cancer drugs.
Oncoprotein-targeted drugs hold enormous promise 
for the future of cancer treatment. However, complete 
clinical responses are rare, suggesting that mechanisms 
exist to render a substantial proportion of tumor cells 
resistant to treatment. Biomarker analysis of tumors fol-
lowing MAPK pathway inhibition of MEK by binimetinib 
demonstrated that, the tumor genetic landscape was 
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concordant with what was reported in the TCGA mela-
noma database. Driven primarily by CDKN2A altera-
tions, the cell cycle pathway was frequently altered in 
patients with the BRAF mutation. Several patients had 
amplification of genes on the q-arm of chromosome 7. 
Three of 7 of these patients had a PFS that was lower than 
the median PFS for the BRAF-mutant population, sug-
gesting that a gene or genes on 7q may promote MEKi 
resistance. Genes of high interest located on 7q include 
the HGF/MET pair, as well as BRAF itself (van Herpen 
et al., submitted).
Another subtype of melanoma is characterized by 
NRAS mutation that occurs in ~ 20% of patients. Despite 
significant efforts to develop drug specific targeting 
NRAS there are no specific therapies for NRAS mutated 
melanoma. Despite emergence of immunotherapies as 
effective treatments in melanoma, there is still a need 
to develop therapies for these patients, particularly after 
failure of NEMO open-label phase 3 study of binimetinib 
vs dacarbazine in patients with advanced unresectable/
metastatic cutaneous NRAS-mutant melanoma who 
were previously untreated or had progressed on/after and 
who showed improvement in PFS [43].
Pre-clinical data on the BRAF kinase inhibitor vemu-
rafenib showed response rates of more than 50% in 
patients with metastatic melanoma with the BRAF V600E 
mutation. The next phase 3 randomized clinical trial 
comparing vemurafenib with dacarbazine in 675 patients 
with previously untreated, metastatic melanoma with 
the BRAF V600E mutation resulted in improved rates of 
overall and progression-free survival (relative reduction 
of 63% in the risk of death and of 74% in the risk of either 
death or disease progression, as compared with dacar-
bazine (p  <  0.001) [31]. Vemurafenib is a potent inhibi-
tor of V600 mutant BRAF but cutaneous side effects are 
frequent: peculiar cutaneous profile involving epidermis 
and adnexa overlaps with the cutaneous manifestations 
of genetic diseases characterized by activating germ line 
mutations of RAS (RASopathy) [44].
The mutational landscape of melanoma was studied by 
sequencing the exomes of 147 melanomas: among the 
genes, the PPP6C that encodes a serine/threonine phos-
phatase was found exclusively in tumors with mutations 
in BRAF/NRAS. This activating mutation changes Pro29 
to serine  (RAC1P29S) promoting melanocyte proliferation 
and migration, with possible therapeutic potential [45].
Furthermore, sequencing allows to investigate acquired 
chemotherapeutic resistance of cancer: the sequenced 
exomes of 27 lesions from three metastatic melanoma 
patients treated with targeted or non-targeted inhibi-
tors showed that BRAF and NRAS co-mutations are not 
mutually exclusive. However, the sole finding of dou-
ble mutated cells in a resistant tumor is not sufficient to 
determine follow-up therapy; these findings demonstrate 
that, in order to target the large pool of heterogeneous 
cells in a patient, the combinational therapy targeting dif-
ferent pathways is required [46].
In conclusion, immune checkpoint inhibitors, such as 
anti-CTLA-4 blockade that activates T cells and enables 
them to destroy tumor cells, are effective cancer treat-
ments, but molecular determinants of clinical benefit 
are not defined. Whole-exome sequencing of tumor tis-
sue from melanoma patients treated with ipilimumab or 
tremelimumab including mutational profiling and HLA 
analysis identified the presence of specific tumor neo-
antigens that might explain the therapeutic benefit. This 
and other published study illustrated the importance of 
tumor genetics in defining the basis of the clinical benefit 
from immunotherapy including CTLA-4 and PD-1 path-
way blockade [47].
Combination strategy session
Overcoming radiation‑induced barriers to an immune 
response
Radiation therapy is a highly effective local treatment for 
cancer. Over the past 50 years, sporadic events of tumor 
regression in un-irradiated fields, at distant metastatic 
sites, known as abscopal effects, have been observed: a 
total of 46 reported cases have been identified from 1969 
to 2014 with median radiation dose of 31 Gy, median fol-
low-up of 17.5 months, and median documented time to 
notice the abscopal effect was 2 months [48].
The abscopal effect of radiation has more recently been 
demonstrated to be a result of an antitumor immune 
response induced by radiation effects in the irradiated 
tumor. The rarity of abscopal effects is a consequence of 
the fact that at the time of metastasis cancer is associated 
with a profound and tumor-specific immune-suppressive 
status. Modern immunotherapy, has offered the potential 
for a recovery of an immune response and a synergy with 
immune activation by radiation. The combination with 
immunotherapy has defined a novel role for radiotherapy 
in systemic disease.
Barriers to the potential of radiation to convert a 
tumor into an in  situ vaccine have emerged beyond 
the pre-existing immunosuppressive microenviron-
ment of established tumors. Radiotherapy itself also 
induces some immunosuppressive signals, within and 
beyond the irradiated field. Some trials are ongoing to 
overcome radiation-induced immunosuppression. For 
instance, counter-acting RT-induced immune-suppres-
sion mediated by adenosine, with effect on dendritic 
cells (DC) maturation and T cells recruitment was doc-
umented in several trials (MEDI9447; NCT02503774; 
NCT01283594). Recent findings demonstrate in murine 
models that CD73-blockade reduces radiation-mediated 
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T regulatory cells (Tregs) infiltration while promoting 
CD8+ T cell infiltration and combined RT and anti-
CD73 treatment delays tumor progression and prolongs 
survival. These data suggest that targeted CD73 therapy 
helps radiotherapy by enhancing the adaptive immune 
response machinery, which may increase the function of 
tumor-infiltrating T lymphocytes, and subsequently lead 
to improved survival in cancer patients.
Another approach regards overcoming TGFβ activa-
tion by radiation-induced ROS, a mechanism that hin-
ders priming of anti-tumor T cells. Vanpouille-Box et al. 
demonstrated that antibody-mediated TGFβ neutraliza-
tion during radiation therapy effectively generates CD8+ 
T cell responses to multiple endogenous tumor antigens 
in poorly immunogenic mouse carcinomas. Generated T 
cells were effective at mediating regression of irradiated 
tumors and non-irradiated lung metastases or synchro-
nous tumors (abscopal effect). Gene signatures associ-
ated with IFNγ and immune-mediated rejection were 
detected in tumors treated with radiation therapy and 
TGFβ blockade in combination but not as single agents. 
However, up-regulation of programmed death ligand-1 
and -2 (PD-L1 and 2) in neoplastic and myeloid cells and 
PD-1 on intratumoral T cells limited the persistence of 
tumor rejection, resulting in rapid recurrence. Addition 
of anti-PD-1 antibodies enhanced the immune response 
and extended survival of the animals treated with radia-
tion and TGFβ blockade. Thus, TGFβ is a fundamental 
regulator of radiation therapy ability to generate an in situ 
tumor vaccine and its systemic effects are enhanced by 
PD-1 blockade. The combination of local radiation ther-
apy with TGFβ neutralization and PD-1 blockade offers 
a novel individualized strategy for vaccinating patients 
against their tumors [49].
Tumor-infiltrating myeloid cells (TIM), including 
CD11b (Integrin subunit alpha, ITGAM)þF4/80 (EMR1)
b protein positive tumor associated macrophages, and 
CD11bþGr-1 (LY6G)þ myeloid-derived suppressor cells 
(MDSC) respond to cancer-related stresses and promote 
tumor angiogenesis, tissue remodeling, and immunosup-
pression. While the role of myeloid derived suppressor 
cells is complex, radiation increases both macrophages 
and MDSC. Enhanced macrophage migration induced by 
conditioned media from irradiated tumor cells was com-
pletely blocked by a selective inhibitor of CSF1R. Mecha-
nistic investigations revealed the recruitment of the DNA 
damage-induced kinase ABL1 into the nucleus where it 
bound the CSF1 gene promoter resulting in CSF1 gene 
transcription. When added to radiotherapy, a selective 
inhibitor of CSF1R suppressed tumor growth more effec-
tively than irradiation alone. The CSF1/CSF1R signaling 
to recruit TIMs likely limits the efficacy of radiotherapy. 
Thus, CSF1 inhibitors should be evaluated in clinical 
trials in combination with radiotherapy as a strategy to 
improve outcomes [50].
Investigations to define the optimal dose, fractiona-
tion and field size of radiotherapy when combined with 
immunotherapy are ongoing. When combined RT with 
concurrent chemotherapy, radiation can cause severe 
treatment-related lymphopenia (TRL) (< 500 cells/mm3) 
that is associated with reduced survival. Severe TRL was 
observed in more than 40% of glioma patients 2 months 
after initiating chemo-radiation, an effect that was inde-
pendently associated with shorter survival from tumor 
progression [51]. Yovino et  al. modeled these effects in 
an attempt to predict the consequences of radiation-
related variables, such as the number of fractions, the 
field size and the dose rate on circulating lymphocytes 
[52]. The model proposed is based on the assumption 
that a single radiation fraction delivers 0.5  Gy to 5% of 
circulating cells. Consequently, 99% of circulating blood 
would receive ≥  0.5  Gy after 30 daily fractions. Reduc-
ing the number of fractions and the field size significantly 
decreases the exposure of circulating mononuclear cells 
during treatment [52]. Confirming this model, a ret-
rospective study in locally advanced pancreatic cancer 
demonstrated significantly less severe radiation-induced 
lymphopenia from stereotactic body radiation than 
standard radiotherapy, that utilizes larger fields and more 
fractions of radiation [53]. Novel approaches are needed 
to limit radiation to circulating lymphocytes given the 
association of lymphopenia with poorer survival in 
patients.
In conclusion, radiotherapy induces both pro-immu-
nogenic and immunosuppressive effects. RT reduces 
circulating lymphocytes rendering blood an “organ at 
risk”, especially for combination with immunotherapy. 
Multiple immunotherapy strategies may be required to 
circumvent both pre-existing and RT-induced immune-
suppression with a strategy that combines hypo-fraction-
ated, short courses of RT to small targets likely to be key 
to the success of RT + immunotherapy.
Where are we really with clinical trials of combination 
immunotherapy?
There are two ways to think about combination 
immunotherapy:
1. Indirect methods: eradicate the tumor with immu-
nogenic stimulus for example including radiotherapy, 
chemotherapy, oncolytic viral therapy or targeted 
therapy.
2. Direct methods include activating T cells through 
agonistic or antagonistic antibodies through co-stim-
ulatory targets or turning off inhibitory receptors on 
T cells, respectively.
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There are several targets with emerging data in mela-
noma, and this report selects a few for discussion.
OX40 is a co-stimulatory receptor that can potentiate 
T cell receptor signaling on the surface of T lymphocytes. 
In an OX40 phase I Trial, a mouse mAb that agonizes 
human OX40 signaling in patients with advanced cancer 
showed an acceptable toxicity profile and regression of at 
least one metastatic lesion in 12/30 patients [54]. Maxi-
mum tolerated dose was not reached (some fevers/chills, 
rash, fatigue, arthralgias); tumor regressions without for-
mal RECIST partial responses; two patients with mela-
noma had mixed responses [54]. Phase I investigations of 
OX40 agonists are ongoing in multiple solid tumors and 
in combination with PD-1 and PD-L1/2 partial responses 
(RCC and UCC) were reported in 2016 [55].
Other co-stimulatory agonist drugs have been clinically 
evaluated in early phase trials with some early activity 
such as urelumab and utomilumab targeting activating 
receptor CD137/4-1BB. Ongoing studies in combination 
with PD-1: utomilumab plus pembrolizumab have also 
been conducted with results indicating that this combi-
nation is well tolerated with some responses being seen 
in solid tumors [56].
Another strategy involves blocking an intratumoral 
enzyme “checkpoint” called indoleamine 2,3 dioxygenase 
(IDO) a tryptophan-catabolizing enzyme that induces 
immune tolerance by T-cell suppression. IDO depletes 
tryptophan and produces toxic kynurenine. Epacadostat 
is an oral, potent, selective inhibitor of IDO1 and pre-
liminary results from ongoing study of epacadostat with 
pembrolizumab showed promising clinical activity and 
acceptable safety profile. A dose expansion (epac 50, 100, 
and 300  mg BID  +  pembrolizumab 200  mg IV Q3  W) 
was then implemented (n  =  22), showing a ORR in 19 
untreated patients equal to 58%, and median PFS has not 
been reached [57]. Epacadostat is now in phase 3 study 
with pembrolizumab.
Combinations have been studied based on preclini-
cal rationale and clinical evidence for efficacy as single 
agents. Early phase combination dose-finding studies 
and then ultimately randomized studies with an overall 
survival endpoint have been then implemented. Ipili-
mumab and GM-CSF combination has better overall 
survival than ipilimumab alone (HR 0.64 for OS) in a 
phase 2 study [58]. In a 2-year assessment of the phase 
2 CheckMate-069 trial, the 2-year OS rate with the com-
bination of nivolumab + ipilimumab was 69% compared 
with 53% for ipilimumab alone (many patients crossed 
over to nivolumab), for patients with BRAF wild-type 
melanoma [59]. The median OS among patients was not 
been reached with the combination regimen and was 
24.8  months with ipilimumab monotherapy (HR, 0.58, 
95% CI 0.31–1.08). In the overall study population, the 
2-year OS rate was 64% with the combination compared 
with 54% for ipilimumab alone (HR, 0.74; 95% CI 0.43–
1.26). The median OS at 2 years in patients randomized 
to either the combination or monotherapy has not been 
reached [60].
However, demonstrating overall survival benefits in 
randomized trials will be increasingly difficult due to the 
limited number of patients with melanoma available for 
trials and higher landmark overall survival metrics. New 
ways to test combinations are required. Should we add 
combinations to PD-1 non-responders or start combi-
nations for “biomarker unfavorable” patients? Multiple 
combinations are partnering with PD-1, but should we 
reconsider ipilimumab combinations in the PD-1 refrac-
tory setting?
Neoadjuvant Trials are also being conducted. Their 
advantages are quick interpretation of drug effect, and 
they have pre-and post-treatment tissue available for 
pharmacodynamic analyses. Whether effects on macro-
metastatic disease in the neoadjuvant setting resemble 
efficacy against micrometastases in the neoadjuvant set-
ting remain unknown. There is also the question of tox-
icity of systemic therapy in patients otherwise cured by 
surgery alone.
In conclusion, combinations are now testing multiple T 
cell regulators, intratumoral “checkpoints”, and standard 
anticancer agents. Reconsidering clinical trial endpoints 
other than overall survival will be needed. Neoadjuvant 
studies may offer unique opportunities.
Sequencing and combinations of checkpoint inhibitors 
with targeted agents in melanoma
Immunotherapy has been a highly promising approach 
of melanoma treatment. Targeting BRAF mutation in 
patients harboring mutated gene has been shown to be 
also highly efficacious. Dual BRAF and MEK inhibition 
is associated with high response rates and median PFS 
(mPFS) of 9–12 months and superior survival compared 
to single-agent BRAF inhibitors (BRAFi) [61–63].
Comparison of systemic therapy for advanced (unre-
sectable Stage III or Stage IV) melanoma reported in 
Table  1 shows similar efficacy in the median patient 
response, PFS and survival in selected group of patients.
Thus, combining targeted therapy with immunother-
apy may lead to enhanced anti-tumor response and result 
in durable responses and prolonged survival (Fig. 1).
The critical issue for designing effective combination 
of anti-BRAF and immunotherapy relies on determina-
tion of optimal selection of targeted and immune ther-
apy agents and identification of biomarkers predictive of 
treatment response that will lead to rational combinato-
rial “regimens”. Retrospective analysis of overall survival 
(OS) revealed improvement in patients treated with 
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ipilimumab compared with those treated with BRAF 
inhibitors first [64]. Another retrospective analysis from 
four major academic centers suggests that either BRAFi 
or anti-PD-1 may be effective regardless of treatment 
sequence in patients with BRAFV600-mutant melanoma, 
but clinical outcomes to front-line therapy are superior 
[65].
The data suggests that BRAFi as a salvage strategy may 
not be highly active in the subgroup that fails anti-PD-1 
and front-line BRAF/MEK inhibitor therapy should be 
considered. Patients who benefited from BRAF-directed 
therapy for  ≥  6  months had a 34% overall response 
rate (ORR) to subsequent anti-PD-1 (11 of 32 patients 
responded). Patients who benefited for < 6 months subse-
quently had a 15% ORR to anti-PD-1 (4 of 26; p = 0.04). 
Shared “phenotype “to predict response for BRAFi and 
anti-PD-1 therapy may exist and studies of molecular 
characterization of “responders vs. resistant phenotype” 
are on the way. If successful, the identified profile may 
serve as a selection marker for prospective studies. It is 
suggested that there is a difference in the molecular pro-
file of tumors responding to CTLA-4 vs PD-1. In the ideal 
scenario, molecular profiles identifying targeted therapy 
responders should not overlap with immune therapy 
responders to provide a benefit of combination therapy.
Resistance is a clinical problem and genetic mecha-
nisms of acquired resistance are diverse [66]. Multiple 
genetic ways of reactivating the MAPK pathway have 
been identified. Besides, mechanisms of intrinsic resist-
ance are not less diverse; one of the major drivers of 
intrinsic resistance seen in AXL-high at baseline [67].
Reduction in circulating tumor DNA (ctDNA) BRAF 
level is associated with tumor regression by RECIST: 
maximum ctDNA BRAFV600 level reduction occurs in 
Cycle 2 and 3 time points in vemurafenib treated patients 
and in at least Cycle 4 in patients treated with the com-
bination of dabrafenib and trametinib. Average, a detect-
able increase in BRAFV600E level was seen  ~  50  days 
in patients treated with BRAF directed therapy prior to 
radiographic PD [68].
Recommendations from the “SWITCH 2.0” Trial for 
optimal strategies for treatment of melanoma patients 
include:
1. BRAFV600 positive tumor melanoma patients, front-
line treatment.
2. Group 1 treated with BRAFi/MEKi until RECIST 
1.1 progressive disease (PD) and then switched to 
ipilimumab/nivolumab, possibility to switch again to 
alternative BRAFi/MEKi.
3. Group 2 treated with BRAFi/MEKi until BRAF level 
first increase (or set at four cycles) and switched 
prior to RECIST 1.1 to ipilimumab/nivolumab with 
Table 1 Comparison of systemic therapy for advanced (unresectable stage III or stage IV) melanoma
Treatment RR (%) PFS (med), months OS (med/2‑years)
Single-agent BRAFi 50 6–8 18.7 months/~ 40%
Combo BRAFi and MEKi 65–70 9–12 15 months/~ 50%
Ipilimumab 10 2–3 12 months/~ 30%
(20% 5 year survival)
Anti-PD-1 mAb (nivolumab or pembrolizumab) 25–45 ~ 6 18–24 months/~ 50%
Combo ipilimumab and nivolumab ~ 60 11–12 Unk./~ 64%
Fig. 1 Melanoma survival curves depending on the type of therapy (modified from [150])
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possibility to switch back to BRAFi/MEKi again if PD 
(alternative type of inhibitors).
4. Primary endpoint: PFS to ipilimumab/nivolumab 
between Groups 1 and 2, ORR, PFS from switch 1 to 
the end of second round of BRAF/MEK (where the 
strategy used).
5. Compare molecular profiles at diagnosis, after each 
line of therapy and at the time of ultimate resistance 
development (will differ based on intrinsic patient 
characteristics and types of therapy).
Building rational combinatorial “regimens” is the 
important factor. BRAFi effects on tumor microenvi-
ronment predict optimal combination with anti-PD-1/
PD-L1 inhibition [69]. Preclinical data predicted synergy 
between MAPK targeting and PD-1/PDL1 inhibition [70, 
71].
A phase Ib dose-escalation and -expansion study 
(NCT01988896) study combining atezolizumab and 
cobimetinib in metastatic melanoma suggested higher 
ORR/disease control rate [durable response rate (DCR), 
overall response rate (ORR) + stable disease] and longer 
PFS with the combination. Updated safety and efficacy 
data (Oct 12, 2016) showed that RECIST v1.1-confirmed 
ORR was 45.0% in patients with non-ocular melanoma 
(median duration of response was not reached); DCR 
was 75.0%; mPFS was 12.0 months (95% CI 2.8–not eval-
uable). ORR was similar for patients with BRAF-mutant 
and wild-type melanoma; adverse events (AEs) were 
experienced in all patients and related grade (G) 3–4 in 
54.5% were most common; related serious AEs in 13.6% 
[72]. A phase 3 trial evaluating atezolizumab  +  cobi-
metinib vs anti-PD-1 therapy in patients with BRAF wild-
type advanced melanoma is planned.
Targeted therapy with MEK inhibitor cobimetinib 
(cobi)  +  BRAF inhibitor vemurafenib in BRAFV600-
mutant melanoma can result in anti-cancer immune acti-
vation and rapid clinical response. Inhibition of PD-L1 
using atezolizumab can lead to anti-cancer immune 
activity and durable responses. Combining these agents 
may enhance antitumor immune activity and potentially 
improve both rate of clinical response and durability 
[69]. In this study 13/14 patients (93%) showed responses 
(RECIST v1.1), including 1 CR and 12 PRs and 11/13 
pts continue in response. One patients with PR had a 
100% reduction in target lesions. Responses were uncon-
firmed, and median DOR and PFS were not evaluable 
due to limited follow-up at the time of data cut (Feb 15, 
2016). Functional biomarkers data of T-cell activation are 
ongoing.
Triple combination treatment was generally well tol-
erated as no unexpected AEs including grade 5 AEs 
occurred. All AEs were manageable and reversed with 
dose interruption and/or reduction. Treatment-related 
serious AEs including grade 3 blood creatinine phos-
phokinase levels increased (cobi-related), grade 4 sepsis 
(cobi-and/or vem-related), grade 3 diarrhea and ALT/
AST levels increased (atezo- and/or cobi- and/or vem-
related); all 3 patients continued on study treatments 
after interruption [73].
In conclusion, atezolizumab  +  cobimetinib demon-
strated encouraging antitumor activity. However, it is 
not known whether the effect is additive or synergistic. 
Overall, ORR was 45% and mPFS was 12.0 months (ate-
zolizumab monotherapy in cutaneous melanoma: ORR, 
33%; mPFS, 5.5  months). The clinical benefit of atezoli-
zumab +  cobimetinib was seen regardless of BRAF sta-
tus. BRAF mutant: ORR was 40%; mPFS, 11.9  months; 
BRAF wild type: ORR was 50%; mPFS, 15.7  months. 
Atezolizumab  +  cobimetinib had a manageable safety 
profile in metastatic melanoma, similar to that observed 
with atezolizumab alone or cobimetinib +  vemurafenib 
combination. The combination atezolizumab  +  cobi-
metinib + vemurafenib had a manageable safety profile in 
patients with BRAF V600 mutant metastatic melanoma, 
but liver toxicity seems to be higher. The triple combina-
tion demonstrated promising antitumor activity, uncon-
firmed response rate was 83% (95% CI 64.2, 94.2).
The question remains whether to start the treatment 
with the combination of different agents including tar-
geted agents, immunotherapy with checkpoints inhibi-
tors, novel approaches) or add/switch on progression.
Other challenges in the optimal use of BRAF/MEK and 
immunotherapy are:
1. Incorporating novel agents-both targeted (AXLi) and 
immunotherapy (TLR9, T-VEC).
2. Postponing large phase 3 trials until we have identi-
fied better markers for patients’ selection.
3. Use of the data from early phase trials.
4. Need for model systems-surrogate markers (in vivo 
imaging, liquid biopsies).
Innovative combination strategies: oncolytic and systemic 
therapy
Oncolytic therapy is a therapeutic modality of direct 
injection at the tumor site agents that may induce a 
local and systemic effect that is immunologically medi-
ated and produce regression. The field of oncolytic 
virotherapy encompasses the use of viruses with natu-
ral or engineered tumor-selective replication to infect 
and kill tumor cells. The main intralesional (IL) agents 
currently in phase 3 trials are viral based (Talimogene 
laherparepvec, TVEC, HF-10, CAVATAK) and non-viral 
based (PV-10, IL-12). The mechanism of action is cell 
lysis (viral replication, chemical and mechanical ablation) 
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and indirect “bystander response” by induction of innate 
immune response and adaptive immune response.
For an anticancer immune response to lead to effective 
killing of cancer cells, a series of stepwise events must be 
initiated and allowed to proceed and expand iteratively. 
We refer to these steps as the cancer-immunity cycle 
which manages the delicate balance between the recogni-
tion of nonself and the prevention of autoimmunity [74].
Intralesional oncolytic therapy in soft tissue and skin 
metastases has shown good safety profile and a durable 
response rate. Local–regional control of tumor growth is 
clinically important, whilst the systemic therapy may not 
always be possible or appropriate. Newer IL agents that 
have the ability to trigger a systemic immune effect can 
be clinically useful for combination treatment. Melanoma 
intra-lymphatic metastasis occurs in 3–10% of primary 
melanoma patients and it manifests clinically as local/
in-transit recurrences. High risk groups for this pres-
entation are characterized by thick, ulcerated, positive 
sentinel lymph nodes (SLN), lower extremity and greater 
than 50% risk of distant disease and death. Intralesional 
approaches may be applicable in melanoma treatment of 
these population of patients.
Current clinical trials with IL agents include monother-
apy with PV-10 (phase III trial is ongoing, IL-12 admin-
istered by electroporation (EP), oncolytic Picornavirus, 
and Coxsackievirus A21 (CAVATAK™). Combination tri-
als with TVEC, PV-10, HF10-oncolytic HSV1 and Reovi-
rus (HF-10) are also ongoing.
PV-10 is an investigational new drug containing a pro-
prietary injectable formulation of Rose Bengal disodium 
(10% RB). It is a small molecule fluorescein derivative 
lysing primary tumors by entering lysosomes, activat-
ing tumor-infiltrating lymphocytes at the local site and 
regression of distant tumors. Necrotic tumor cells have 
been shown to facilitate antigen presentation and the 
secondary tumors are rejected in immuno-competent 
animals. Responses are tumor specific and no immune 
response was reported in immuno-compromised ani-
mals. Adoptive transfer of spleen cells can convey 
immunity because T cell subsets have increased expres-
sion of IFNγ. A phase 2 study of intralesional PV-10 in 
refractory metastatic melanoma assessing efficacy and 
safety of PV-10 in 80 patients with refractory cutane-
ous or subcutaneous metastatic melanoma showed 
encouraging results. The best overall response rate for 
targeted lesion was 51%, and the complete response rate 
was 26%; median time to response was 1.9 months, and 
median duration of response was 4.0  months, with 8% 
of patients having no evidence of disease after 52 weeks 
[75]. Regression of bystander lesions strongly correlated 
with response in target lesions and responses occur early 
as 56% of lesions achieved complete response (CR) after 
1–2 injections. An open-label, randomized controlled 
trial of single-agent intralesional PV-10 versus systemic 
chemotherapy or intralesional oncolytic viral therapy is 
currently ongoing to assess treatment of locally advanced 
cutaneous melanoma in patients who have failed or are 
not otherwise candidates for targeted therapy and have 
failed or are note candidates for at least one immune 
checkpoint inhibitor. An international multicenter, open-
label, sequential phase study of intralesional PV-10 in 
combination with pembrolizumab in stage IV metastatic 
melanoma patients with at least one injectable cutane-
ous or subcutaneous lesion (NCT02557321) is ongoing. 
In the phase 1b portion of the study, all participants will 
receive the combination of IL PV-10 and pembrolizumab 
(i.e., PV-10 + standard of care). In the subsequent phase 
2 portion of the study participants will be randomized 1:1 
to receive either the combination of IL PV-10 and pem-
brolizumab or pembrolizumab alone (i.e., PV-10 + stand-
ard of care vs. standard of care).
The Intratumoral DNA-encoded IL-12 Electroporation 
(IT-pIL12-EP) is a DNA plasmid encoding interleukin-12 
(IL-12), a potent pro-inflammatory cytokine. It is deliv-
ered directly to tumor in vivo by electroporation. Trans-
fection of the plasmid stimulates local immune response 
and subsequently, systemic effect. Thirty patients with 
stage IIIB-IV melanoma received up to four cycles of 
IL-12 EP into superficial cutaneous, subcutaneous, and 
nodal lesions on days 1, 5 and 8 of each 12-week cycle. 
The treatment induced objective tumor responses in a 
significant proportion of patients (31%) and treatment 
was well tolerated [76].
CAVATAK, is a bioselected oncolytic strain of Cox-
sackievirus A21 (CVA21) is another oncolytic immuno-
therapy agent. Following intratumoral injection, CVA21 
preferentially infects ICAM-1 expressing tumor cells, 
resulting in viral replication, cell lysis, and a systemic 
anti-tumor immune response. The phase II CALM 
study investigated the efficacy and safety of IT CVA21 in 
patients with advanced melanoma. The primary endpoint 
of the study was achieved in 38.6% evaluable patients 
with durable responses observed in both injected and 
uninjected melanoma metastases, suggesting the genera-
tion of systemic host anti-tumor responses [77].
Talimogene laherparepvec (T-VEC) is an intralesional 
oncolytic virus based on a modified herpes simplex 
virus type-1. It selectively targets tumor cells, causing 
regression in injected lesions and inducing immuno-
logic responses that mediate regression at uninjected/
distant sites. In a randomized phase 3 trial, T-VEC 
met its primary endpoint of improving the durable 
response rate vs granulocyte–macrophage colony-stim-
ulating factor (GM-CSF) in patients with unresectable 
melanoma [78]. Responses were observed in injected 
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and uninjected regional and visceral lesions. Explora-
tory analyses suggested survival differences in favor of 
T-VEC in patients with untreated or stage IIIB/IIIC/
IVM1a disease. T-VEC therapy was generally well tol-
erated, the most common adverse events being flu-like 
symptoms [79].
OPTiM was a randomized, phase 3 trial of T-VEC or 
GM-CSF in patients with unresected melanoma with 
regional or distant metastases. The primary endpoint 
was durable response rate (DRR): partial or complete 
response (CR) continuously for  ≥  6  months starting 
within 12  months. Objective response rate with T-VEC 
was 26% (95% CI 21, 32%) with 11% CR, and with GM-
CSF was 6% (95% CI 2, 10%) with 1% CR. DRR for T-VEC 
was 16% (95% CI 12, 21%) and 2% for GM-CSF (95% CI 
0, 5%), p < 0.0001. DRR by stage (T-VEC, GM-CSF) was 
IIIB/C (33, 0%), M1a (16, 2%), M1b (3, 4%), and M1c (8, 
3%). Interim OS showed a trend in favor of T-VEC; HR 
0.79 (95% CI 0.61, 1.02) which did not reach statistical 
significance. Most common adverse events (AEs) with 
T-VEC were fatigue, chills, and pyrexia. Serious adverse 
events (AEs) occurred in 26% of T-VEC and 13% of GM-
CSF pts. No  ≥  grade 3 AE occurred in  ≥  3% of pts in 
either arm [80].
Preliminary data suggest higher CR and OR rates than 
either agent alone and earlier responses after ipilimumab 
initiation during T-VEC  +  ipilimumab than with ipili-
mumab alone [81]. A phase 1b demonstrated that of 17 
pts with investigator assessed response, ORR was 41% 
(24% CR, 18% PR); 35% had stable disease (SD). Median 
time to response was 2.9 months. Activated CD8 T cells 
numbers significantly increased from baseline 1.8× after 
T-VEC alone and 2.9× during T-VEC  +  ipilimumab 
treatment; Gr 3/4 AEs occurred in 32% as determined by 
flow cytometry [82].
ORR was higher for T-VEC in combination with  ipili-
mumab vs ipilimumab alone [83]. Confirmed ORR was 
35.7% (T + I) and 17.5% (I); unconfirmed ORR was 50% 
(T +  I) and 27.5%. AEs were comparable between arms 
except for increased fatigue, chills, and pyrexia in the 
T + I arm [83].
The combination of T-VEC and pembrolizumab dem-
onstrated improved clinical benefit in a phase 1b/2 study 
in unresectable stage IIIB-IV melanoma with all patients 
having started on T-VEC + pembrolizumab ≥ 6 months 
prior [84]. Per immune related criteria (irRC), in 21 pts, 
confirmed/not yet confirmed objective response rate 
(ORR) was 48%/57%; CR rate was 14%/24%. Median time 
to response was 17 wks. Circulating CD8+ T cells includ-
ing those expressing defined immune modulatory recep-
tors (e.g., Tim3, BTLA) became elevated during therapy 
with T-VEC initially but decreased after pembrolizumab 
began on d 36 [84].
A phase 1b on subjects treated with MK-3475 (pem-
brolizumab) until CR disease progression per irRC, 
or intolerance of study treatment, up to a maxi-
mum of 24  months of study treatment is ongoing 
(NCT02263508). In phase 3, subjects will be treated 
with T-VEC plus pembrolizumab (arm 1) or placebo plus 
pembrolizumab (arm 2) until 24 months from the date of 
the first dose of pembrolizumab or end of treatment due 
to disappearance of injectable lesions, complete response, 
disease progression per irRC-RECIST or intolerance of 
study treatment.
HF10 is not genetically engineered but is a nonselec-
tive clone from the non-neuroinvasive HSV-1 strain 
HF. Apart from loss of UL56 gene, sequencing of HF10 
revealed an overall 99.1% similarity to HSV-1 strain 17, 
with mutations in genes involved in regulation of syncy-
tia formation including UL1, UL20, UL22, UL24, UL27, 
and UL53. HSV strains can spread from cell-to-cell via 
infection across the junctions between the membranes 
of adjacent cells (wild-type strains (syn+) or by fusion of 
the infected cell with adjacent uninfected cells leading to 
the formation of multinucleated polykaryocytes or syn-
cytia [syncytial mutant strains (syn)]. Interestingly, HF10 
induces syncytia formation in vitro, and did not result in 
the cytopathic effect observed in hrR3 infected cells [85]. 
It is characterized by greater replication ability, result-
ing in lower effective dose and no toxicity resulting from 
inserted exogenous gene (ex. GM-CSF). Attenuation of 
neurovirulence to be attributable to the lack of the UL56 
gene (lack of UL56 gene decreases HSV-1 pathogenicity 
without affecting viral replication ability). In addition to 
local oncolytic tumor destruction, systemic anti-tumor 
immune response observed.
Preliminary data of the antitumor activity of 
HF10  +  ipilimumab combination in an ongoing phase 
2 trial in melanoma on 43 patients enrolled and treated 
at abstract data cut-off 01 Feb16 show that majority of 
HF10-related AEs are ≤ G2, similarly to HF10 monother-
apy and consistent with other oncolytic viruses. No DLTs 
or ≥ G4 AEs were reported. G3 AEs were experienced by 
11.6% of pts. Of 37 efficacy evaluable patients, BORR by 
irRC at 24 weeks is 37.8% (13.5% CR and 24.3% PR) and 
disease stability rate is 56.8% (18.9% SD) [86].
Pro and con arguments of the role for IL monotherapy 
are reported in Table 2.
In conclusion, soft tissue and cutaneous metastases are 
a major clinical problem in melanoma. Oncolytic intral-
esional approaches may have value as local direct effect, 
systemic immune effect and low toxicity. Several agents 
in development appear promising such as TVEC that was 
approved by US and EU regulators. Combination thera-
pies are likely to be the future and may be the best way to 
integrate them into clinical practice.
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System biology session: immunology
Rational design of combination immunotherapy
Effective immunotherapy is a balance between induction 
of immune response (NK, B cell, CD4 cells, CTL) and 
inhibition of suppression (Tregs, MDSC, TAM, IDO). 
Biologically rational design of immunotherapeutic com-
bination is crucial for the success of such approach.
The PD-1 receptor is a negative regulator of T-cell 
effector mechanisms that limits immune responses 
against cancer: lambrolizumab was tested in patients 
with advanced melanoma and showed a high rate of sus-
tained tumor regression, with mainly grade 1 or 2 toxic 
effects [87]. In patients with melanoma, ipilimumab pro-
longs overall survival, and nivolumab produced durable 
tumor regression in a phase 1 trial. Based on their dis-
tinct immunologic mechanisms of action and supportive 
preclinical data, a phase 1 trial of nivolumab combined 
with ipilimumab in patients with advanced melanoma 
showed a rapid and deep tumor regression in a substan-
tial proportion of patients; a total of 16 out of 53 patients 
had tumor reduction of 80% or more at 12 weeks, includ-
ing 5 with a complete response [88]. Accordingly, pre-
liminary data of early clinical trials of such combination 
proved better than the effect of each of the single agents.
Other immunomodulatory agents that may come into 
play in the spectrum of combination therapy include 
immune agonists antibodies of activating receptors such 
as anti-OX40 and anti-GITR. Anti-OX40 enhances T 
cell responses and is associated with increased T cell 
expansion/proliferation, effector function, T cell sur-
vival, T cell memory development as well as enhancing 
vaccine therapeutic effect. Accordingly, the combina-
tion of anti-OX40 and anti-PD-1 is a rational strategy in 
immune therapy combination development. Few clini-
cal trials are currently being conducted combining these 
two agents. Interestingly, we found that the sequence of 
such combination is crucial for its success or failure. In 
addition, combining OX40 agonist antibody enhances 
specific immune response in pre-primed animals with 
tumor specific antigens. This enhancement leads to bet-
ter tumor response that is immune-dependent. However, 
when anti-PD-1 is combined concomitantly with ago-
nist anti-OX40, surprisingly, we found that it completely 
abrogates the immune response of OX40 and hence 
eliminates the tumor response induced by the agonist 
antibody [89]. We also found, that blocking PD-1/PD-L1 
pathway while activating OX40 drives the CD8 T cells 
into apoptotic cell death [89]. Accordingly, it is crucial 
to know that combining two immune modularity agents 
is not a straightforward approach and such combination 
may not induce a desirable response if not treated in the 
proper sequence. In a combination approach, any of the 
agents could lead to changes within the tumor microen-
vironment that produce a specific immune effect which 
may influence the outcome of the second immunomodu-
lator in a potentially positive or a negative manner.
Naturally occurring T regulatory cells (Tregs) express 
the transcription factor Foxp3, which is a master regula-
tor of Tregs development and function. The Foxp3 gene 
was first identified as the defective gene in the mouse 
strain Scurfy. Scurfy is an X-linked recessive mutant that 
is lethal in hemizygous males within a month after birth. 
Hypoxia, or low oxygen tension, is a major regulator of 
tumor development and aggressiveness. Accordingly, 
strategies to decrease Tregs are important to be included 
within the combination repertoire to further enhance 
the outcome of therapeutic approaches. Cyclophospha-
mide used in low metronomic doses have been shown to 
decrease Tregs in the microenvironment and enhance the 
anti-tumor immune effect [90]. Based on that, we found 
that combining antigen-vaccine with anti-PD-1 and a 
single dose of low-dose cyclophosphamide can improve 
immune outcome [91]. Utilizing Listeria as a platform 
for cancer vaccine to generate antigen-specific anti-
tumor immune response, we found that Listeria exhibit 
a bystander immune response leading to the decrease 
in the ratio of Tregs to CD4 T-cells [92]. It has been 
reported that anti-glucocorticoid-induced tumor necro-
sis factor receptor (GITR) agonist antibodies leads to 
tumor regression only in the context of Tregs depletions 
[93]. Based on that and since Listeria-based immunother-
apy is able to decrease the ratio of Tregs to CD4 T-cells, 
we hypothesized that combining Listeria-based vaccine 
with GITR-agonist antibody would exhibit synergis-
tic anti-tumor immune response. Indeed, listeria-based 
(Lm) immunotherapy combined with agonist anti-GITR 
antibody provide a potent synergistic treatment strat-
egy that simultaneously targets both the effector and 
Table 2 Potential role of intralesional monotherapy
Yes No
Not all patients are candidate for systemic therapy (co-morbidities, toxicity) Systemic therapies in 2015 are safe and effective
After progression on other therapies Melanoma is a systemic disease
Alternative to surgery? Surgery is an instant CR
Neoadjuvant potential Not yet proven
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suppressor arms of the immune system, leading to sig-
nificantly improved anti-tumor efficacy [94].
In summary, unlike most of chemotherapeutic 
approaches to cancer, combination immunotherapy is 
not a random approach of drug coupling, but rather it 
should be based on biologically based rational approach 
to therapy that is intended to redesign the immune com-
position of the tumor microenvironment.
Bioinformatics approaches to investigate mechanisms 
driving the non‑T cell‑inflamed tumor microenvironment
Tumors with substantial susceptibility to anti-PD-1 anti-
body are numerous (melanoma, non-small cell lung can-
cer, renal cell carcinoma—clear cell carcinoma etc.) and 
registrational trials are on-going in many cancer histolo-
gies (gastroesophageal cancer, hepatocellular carcinoma, 
mesothelioma etc.) [95].
The T cell-inflamed tumor microenvironment is char-
acterized by expression of immune-inhibitory pathways 
and predicts patient outcomes to immunotherapy [96, 
97]. The molecular mechanisms that explain the T cell-
inflamed versus non-inflamed tumor microenvironments 
could include though not necessarily be limited to: (1) 
somatic differences at the level of tumor cells charac-
terized by distinct oncogene pathways activated in dif-
ferent patients and mutational landscape and antigenic 
repertoire; (2) germline genetic differences at the level 
of the host (patient) characterized by polymorphisms in 
immune regulatory genes; (3) environmental differences 
characterized by commensal microbiota. Data for each 
of these is now available for melanoma and investiga-
tions are on-going to spread these concepts across tumor 
types.
Regarding cancer cell intrinsic properties and specifi-
cally distinct oncogene pathways, some of T cell exclu-
sion have been elucidated. Only a subset of patients 
responds to blockade of immune-inhibitory receptors 
treatments and the therapeutic benefit is preferentially 
achieved in patients with a pre-existing T-cell response 
against their tumor, as evidenced by a baseline CD8+ 
T-cell infiltration within the tumor microenvironment. 
It is critical to understand molecular mechanisms of a 
spontaneous anti-tumor T-cell response in melanoma-
cell-intrinsic oncogenic pathway that contributes to a 
lack of T-cell infiltration in melanoma [98]. The corre-
lation between activation of the WNT/β-catenin sign-
aling pathway and absence of a T-cell gene expression 
signature was the first tumor-intrinsic molecular sign-
aling pathway identified to mediate immune exclusion. 
Activated β-catenin signaling results in T-cell exclu-
sion and resistance to anti-PD-L1/anti-CTLA-4 mono-
clonal antibody therapy [98]. On a mechanistic level, 
β-catenin represses CCL4 chemokine, leading to lack 
of Batf3+ DC recruitment, failed T cell priming and 
response to checkpoint blockade [98]. Genetic land-
scape of the T cell-inflamed tumor microenvironment 
across The Cancer Genome Atlas (TCGA) solid tumors 
was investigated in order to describe the spectrum of 
the T cell-inflamed tumor phenotype across histologies 
[99]. Studies of mutational burden compared with the T 
cell-inflamed tumor microenvironment showed no cor-
relation between gene expression and mutational bur-
den in any cancer type [99]. Antigen is not rate-limiting 
in non-T cell-inflamed tumors that lack of spontaneous 
immune infiltration in solid tumors is unlikely due to lack 
of antigens. Rather a clear linear association with antigen 
presenting machinery and Batf3 lineage DCs are sug-
gested. As an example of this approach, gene expression 
in testicular germ cell tumor (GCT) revealed a T-cell-
inflamed tumor microenvironment in 47% of testicular 
GCTs, including seminoma (83%) and nonseminoma 
(17%) tumor subtypes [100]. Expression of alpha-fetopro-
tein (AFP) RNA correlated with lack of the T-cell signa-
ture, with increasing AFP RNA inversely correlating with 
the inflamed signature and expression of IFNγ-associated 
genes. These data suggest that GCTs can respond to 
anti-PD-1 and that gene expression profiling supports 
investigation of immunotherapy for treatment of GCTs 
[100]. The presence of intratumoral CD8+ T cells has 
been associated with clinical benefit to immunotherapy 
and patients can be categorized based on the presence 
or absence of a T cell-inflamed tumor microenviron-
ment. Molecular mechanisms underpinning the absence 
of a T cell response are beginning to be understood with 
identification of the WNT/β-catenin pathway playing a 
major role in melanoma including activating mutations 
CTNNB1 and Inactivating mutations in negative regula-
tors of Wnt pathway (Axin1, Axin2, APC1, APC2) [101]. 
Pathway activation without mutation includes overex-
pression of Wnt ligands, Fzd receptors, β-catenin [101]. 
Other tumor-oncogenic pathways correlating with T-cell 
exclusion in the non-T-cell-inflamed tumor microen-
vironment and the resistance to immunotherapies are 
also under investigation. Upregulation of genes encod-
ing immune checkpoint proteins PD-L1, IDO, FOXP3, 
TIM3, and LAG3 was associated with T-cell-inflamed 
tumors, suggesting potential for sensitivity to checkpoint 
blockade. Conversely, β-catenin, PPAR-γ, and FGFR3 
pathways were activated in non-T-cell-inflamed tumors 
[102]. Furthermore, PTEN loss in melanoma associates 
with non-T cell-inflamed tumor microenvironment and 
resistance to anti-PD-1 [103].
The next hurdle in cancer immunotherapy is over-
coming the non-T cell-inflamed tumor microenviron-
ment. Therefore, a number of clinical trials are ongoing 
on different targets, promoting innate immunity/type I 
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IFNs like intratumoral STING agonists, inducing tertiary 
lymphoid structures and modulate stroma (anti-CD40). 
Examples are phase 1 study of stereotactic body radio-
therapy followed by pembrolizumab in advanced solid 
tumor, phase 1 study of SEA-CD40 in advanced malig-
nancies, phase 1b/2 study of BBI608 in combination with 
immune checkpoint inhibitors in advanced solid tumors 
and phase II dual cohort study of gut microbiota modula-
tion with pembrolizumab in melanoma.
In conclusion, anti-PD-1 or PD-L1 immunotherapy is 
becoming standard therapy in many tumor types. T cell 
gene signatures correlate well with available biomarkers 
(including gene expression, mutational load, PD-L1, TCR 
clonality) and clinical benefit. Future immunotherapy 
drug development should be stratified toward engaging 
either the inflamed or non-inflamed tumor microenvi-
ronment (inflamed like IDO, Tregs, MDSCs and non-
inflamed like RT, STING, CD40) and molecular pathways 
leading to immune exclusion (e.g., β-catenin/PTEN).
The gut microbiome and cancer therapeutics
The gut microbiota is composed mostly of bacteria, but 
also fungi, archaea and viruses. Evolutionary develop-
ment of the host immune system has been closely asso-
ciated with the microbiota in a symbiotic relationship 
(eubiosis). This diverse microbiome is associated with 
many diseases including asthma, allergy and inflamma-
tory bowel disease, and is involved in numerous func-
tions including, digestion of complex carbohydrates, 
direct competition for limited nutrients and occupation 
of ecological niches that may otherwise be colonized by 
pathogenic microorganisms [104]. Furthermore, the gut 
microbiota can affect distant organs [105]. Dissecting 
the relationship between the microbiota, pathogens and 
the host may provide novel insights into disease patho-
genesis, as well as novel avenues for the prevention and 
treatment of intestinal and systemic disorders including 
cancer.
During cancer treatment, there is a complex interplay 
between the gut microbiota and anticancer therapies. 
These therapies can exert cytotoxic effects on intestinal 
bacteria, leading to dysbiosis. However, the gut micro-
biota can in turn influence both the therapeutic activity 
and the side effects of anticancer agents, via pharma-
codynamics and immunological mechanisms [106]. 
The antitumor efficacy of immune checkpoint inhibi-
tors including anti-CTLA-4 has been demonstrated to 
require gut microbiota, in particular, gram-negative bac-
teria [107]. Burkholderia cepacia acts in conjunction with 
Bacteroides fragilis to restore sensitivity to anti-CTLA-4. 
Adoptive T cell transfer of T cells primed with B. fragi-
lis ameliorates the antitumor effects of CTLA-4 block-
ade in germ free mice. Anti-CTLA-4 compromises the 
homeostatic equilibrium between Intestinal Epithelial 
Cells (IEC) and intraepithelial lymphocyte, leading to 
the apoptotic demise of IEC in the presence of micro-
bial products. Compensation of mice with B. fragilis + B. 
cepacia was able to protect against subclinical toxicity. 
Furthermore, we saw an increase in IFNγ and a decrease 
in IL-10 production in B. fragilis/Bacteroides thetaio-
taomicron-specific memory CD4+ T cell responses in 
metastatic melanoma patients post-CTLA-4 blockade. 
Feces from metastatic melanoma patients were analysed 
and grouped into three clusters (A, B and C) based on 
genus composition. Germ free (GF) mice transplanted 
with feces from Cluster C patients had a significantly 
greater response to CTLA-4 blockade compared to mice 
which received Cluster B feces and were found to facili-
tate the outgrowth of beneficial B. fragilis. The efficacy 
of anti-CTLA-4 therapy in Cluster B transplanted mice 
could be improved by compensation mice with certain 
bacteria. In conclusion, gut microbiota impacts ther-
apy-induced antitumor immunosurveillance and that 
the therapeutic coverage of immune checkpoint block-
ade could be broadened when a favorable microbiota is 
present.
Next target for immune checkpoint blockade
There is ample evidence that high-level spontaneous and 
vaccine-induced tumor antigen-specific T cells may exist 
in patients with advanced and progressive melanoma. 
This paradoxical coexistence of T cell immune responses 
with melanoma progression has led us to investigate the 
multiple immunoregulatory pathways driving T-cell dys-
function in the tumor micro environment (TME). The 
upregulation of inhibitory receptors by T cells chronically 
activated by tumor cells in the TME represents a major 
mechanism of tumor-induced T cell dysfunction. Target-
ing inhibitory pathways with blocking antibodies have 
transformed the standard of care for patients with mela-
noma and other solid tumors. Anti-PD-1 antibodies are 
a potent therapy for melanoma, which provide clinical 
benefits to 30–40% of patients with advanced melanoma. 
Beyond PD-1, group at the University of Pittsburgh 
has worked on identifying additional inhibitory path-
ways that may cooperate with PD-1 to dampen T cell 
responses to melanoma. There are numerous inhibitory 
receptors expressed by T cells in the TME that bind to 
their respective ligands expressed by antigen-presenting 
cells and tumor cells [108].
The rationale for optimal combinatorial immune check-
point blockades is based on the identification of inhibi-
tory or activating receptors expressed by a significant 
number of tumor antigen-specific CD8+ T cells. The evi-
dence exists of additive/synergistic effects on tumor-anti-
gen specific CD8+ T cell expansion and function upon 
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dual blockade targeting non-redundant inhibitory path-
way. Mouse tumor models support the in vivo efficacy of 
the dual blockade with a nontoxic and safe profile. Based 
on this hypothesis, the group has focused on the novel 
T cell inhibitory receptor with immunoglobulin (Ig) and 
immunoreceptor tyrosine-based inhibition motif (ITIM) 
domains called TIGIT. TIGIT is expressed by T cells 
and NK cells. It competes with the costimulatory mol-
ecules CD226/DNMA-1 for binding to the same ligands 
CD155/PVR and CD112 expressed by antigen-presenting 
cells and tumor cells [109].
TIGIT was shown to be co-expressed with PD-1 by 
tumor antigen-specific CD8+ T cells in melanoma and 
TIGIT ligands are highly expressed in metastatic mela-
noma [110]. Dual TIGIT/PD-1 blockade increases the 
expansion and function of human tumor antigen (TA)-
specific CD8+ T cells. In addition, others have also 
observed that dual PD-1/TIGIT blockade promotes 
tumor regression in multiple mouse tumor models [110].
TIGIT is also upregulated by human Tregs in the 
TME, and TIGIT high CD4+ TILs are highly immuno-
suppressive. Targeting TIGIT with Fc-engineered mAbs 
may prove efficacious to deplete Tregs in patients with 
advanced melanoma.
In conclusion, TA-specific CD8+ T cells in the periph-
ery and at the tumor sites co-express a number of inhibi-
tory receptors in addition to PD-1, including TIGIT. 
TIGIT ligands are highly expressed in the TME of mela-
noma and many other solid tumors. Dual PD-1/TIGIT 
blockade augments the expansion and function of human 
TA-specific CD8+ T cells in  vitro and promotes tumor 
regression in multiple mouse tumor models. These data 
served as the rationale for ongoing clinical trials with 
dual PD-1/TIGIT blockade in patients with advanced 
cancers, including melanoma.
Advancing dendritic cell cancer immunotherapy
In stage D0 prostate cancer, PSA recurrence without evi-
dence of measurable disease is a clinical problem with 
limited treatment options. Immune therapy could delay 
the initiation of androgen deprivation therapy. In fact, a 
pilot study of vaccination with epitope-enhanced T cell 
receptor alternate reading frame protein (TARP) and 
TARP peptide-pulsed dendritic cells for the treatment 
of stage D0 prostate cancer has recently been completed 
[111]. TARP is a novel 58 amino acid protein, expressed 
on 85–95% of prostate cancer specimens, which origi-
nates from prostate epithelial cells, not infiltrating T 
cells. It is expressed on normal prostate epithelium and 
over-expressed in prostate cancer. TARP expression is 
associated with conventional markers of unfavorable 
and more aggressive tumor behavior. The study inves-
tigated TARP peptide vaccination’s impact on the rise 
in PSA [expressed as slope log (PSA) or PSA doubling 
time (PSADT)], validated tumor growth measures, and 
tumor growth rate in men with Stage D0 prostate can-
cer. HLA-A*0201 positive men were randomized to 
receive epitope-enhanced (29-37-9V) and wild-type 
(27–35) TARP peptides administered as a Montanide/
GM-CSF peptide emulsion or as an autologous peptide-
pulsed dendritic cell vaccine, every 3 weeks for a total of 
five vaccinations with an optional 6th dose of vaccine at 
36 weeks based on immune response or PSADT criteria 
with a booster dose of vaccine for all patients at 48 and 
96 weeks [111]. Per protocol, Peripheral Blood Mononu-
clear Cells (PBMCs) were collected by apheresis, PBMCs 
were enriched for monocytes by counter-flow elutria-
tion (20–80%) and aliquots of the monocytes were cryo-
preserved. Subsequently, thawed monocytes culture for 
3 days with IL-4 + GM-CSF and then culture for 1 day 
with LPS  +  IFN-1. On the last day of culture the DCs 
were pulsed with HLA-A2-restricted TARP peptides, 
harvested and infused. 72% (n =  41) of patients reach-
ing 24 weeks and 74% reaching 48 weeks had a decreased 
slope log (PSA) compared to their pre-vaccination base-
line (p = 0.0012 and p = 0.0004 for comparison of overall 
changes in slope log (PSA), respectively). TARP vaccina-
tion also decreased by 50% in median tumor growth rate 
(g): pre-vaccine g = 0.0042/day, post-vaccine g = 0.0021/
day (p = 0.003). 80% of subjects exhibited new vaccine-
induced TARP-specific IFNγ ELISPOT responses but 
these responses did not correlate with decreases in 
slope log (PSA). Thus, vaccination with TARP peptides 
resulted in significant slowing in PSA velocity and reduc-
tion in tumor growth rate in most of patients with PSA 
biochemical recurrence [111].
This study suggests TRAP DC vaccines could be 
improved by understanding lot-to-lot variability and 
better understanding of the mechanisms of action and 
biomarkers associated or predictive of clinical response. 
TARP DCs are autologous therapies and a unique prod-
uct is manufactured for each vaccine, consequently, 
patient factors can contribute to product variability. 
Sources of variability of cellular therapies are starting 
materials (patient biology in terms of genetic, gender, 
race and age), patient disease (type, stage and treatment); 
manufacture related (starting material, separation, 
response to stimuli and metabolism).
A very recent study a subset of stage D0 prostate 
cancer patients treated with TRAP DC vaccines aimed 
to identify DC markers correlating with clinical and 
immunologic response to the vaccination regimen. 
TRAP DCs from 18 vaccinated patients were exten-
sively characterized [112]. Peptide-pulsed DC prepa-
rations were analyzed by gene expression profiling, 
cell surface marker expression and cytokine release 
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secretion, and correlated with clinical and immuno-
logic responses. Characteristics of the final DC prod-
uct were:  >  95% for all products (CD80, CD83, CD86, 
CD123, CD11c, CD38, CD54, and HLA-DR); variable 
expression (CD14: range 14–90%, CCR7: range 5–90%, 
viability: range 37–91%, DC yield range 6–48%). Com-
parison of TARP DCs associated with PSA clinical 
response and non-response showed in responders a 
trend toward higher levels of CCR7 and a trend toward 
lower levels of CD14. Hierarchical clustering and prin-
cipal component analysis of the gene expression data 
revealed that DCs clustered by patient with no separa-
tion of responders and non-responders. A class com-
parison of clinical responders and non-responders 
found 55 differentially expressed genes (false discovery 
rate =  65%). The weighted gene coexpression network 
analysis (WGCNA) method was used for further analy-
sis of the gene expression data. WGCNA is a systems 
biology method, describing correlation patterns across 
microarray samples, it is not biased and it finds clus-
ters or modules of highly correlated genes. This analysis 
found that DCs showing lower expression of a tolero-
genic gene signature induced strong antigen-specific 
immune response and slowing in PSA velocity, a surro-
gate for clinical response. These DCs were also charac-
terized by lower surface expression of CD14, secretion 
of IL10 and MCP-1 (CCL2), and greater secretion of 
MDC (CCL22). When combined, these four factors dis-
criminate DCs inducing strong immunologic response.
In conclusion, tolerogenic TARP DCs are associated 
with a poor immunological and clinical response and 
candidate DC potency markers include CD14, IL-10, 
CCL2 and CCL22. However, lot-to-lot variability is a 
critical issue for DC-based immunotherapies. There is 
no best method to identify cell therapy biomarkers and 
both hypothesis and discovery driven approaches are 
effective. Product variation can be used to better under-
stand mechanism of action and identify potency markers. 
Work is ongoing to improve the consistency of DC-based 
immunotherapies.
Biomarkers session
The promising alliance of electrochemotherapy 
and immunotherapy
Electroporation (EP) consists in the delivery of a lim-
ited number of short and intense electric pulses which 
are defined by an intensity E and a duration t. Above a 
certain threshold of the E and/or t parameters, cell mem-
brane defects appear and result in cell permeabilization. 
After a given lag time, cell membrane integrity is restored 
leading to cell survival.
Electrochemotherapy (ECT) consists in the deliv-
ery of short and intense electric pulses following the 
administration of non- or low-permeant cytotoxic drugs, 
such as bleomycin. Cell membrane permeabilization per-
mits the drug to enter the target cells and eventually to 
trigger cell death through multiple DNA breaks, which 
are lethal for dividing cells.
Electroporation and electroporation-based therapies 
are promising approaches for the treatment of cancer. 
The following medical applications of electroporation 
have already been developed and brought to clinics:
1. Electroporation to transfer drugs and small mol-
ecules is the combination of EP and cytotoxic drugs 
that do not freely cross the plasma membrane. ECT 
was the first application that reached the clinical 
stage. ECT works very efficiently and without major 
side effects. It selectively kills the tumor cells and 
spares the normal non-dividing cells in the volume 
exposed to electric pulses (EPs) (usually eight short 
pulses of 100-μs duration). However, ECT remains 
a local treatment with no obvious effects on distant 
metastases.
 Two anti-cancer molecules bleomycin and cisplatin 
have met these prerequisites and are currently used 
in the clinical practice of ECT. These drugs, once 
internalized into cells via the local delivery of EPs, 
generate DNA lesions, either both single-strand and 
double-strand DNA breaks (if bleomycin is used) 
or adducts and intra-strand and inter-strand DNA 
bonds (if cisplatin is used), ultimately leading to cell 
death.
 After cell electroporation, large amounts of the cyto-
toxic molecules enter cells by diffusion, regardless of 
the cell type. Electroporation thus turns bleomycin 
and cisplatin into very efficient drugs in all tumor 
types, as verified in preclinical and clinical studies. 
A wide range of tumors has been treated by ECT, 
mainly using bleomycin. These now include primary 
tumors (basal cell carcinoma) and metastases of 
head and neck carcinomas, Kaposi’s sarcoma, breast 
adenocarcinoma, and melanoma. Clinical trials are 
nowadays addressing the treatment of deep-seated 
tumors (primary pancreatic carcinoma and bone, 
liver, and brain metastases).
 In addition, ECT demonstrates potent anti-vascular 
effects. A transient vasoconstriction is observed 
following EPs delivery alone, and moreover, the 
endothelial cells forming tumor blood vessels are 
also sensitive to ECT (as any proliferative cell in the 
treated region). Consequently, these phenomena 
result in tumor starvation (lack of oxygen and growth 
factors) and thus contribute to cancer cell death.
 Nowadays, ECT is used in routine in about 140 Euro-
pean cancer centers.
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 Technology was developed in the Cliniporator EU 
project. Then, the EU-funded ESOPE clinical study 
demonstrated an objective response rate of 85% in 
ECT treated tumor nodules, regardless of the tumor 
histology and drug used or route of its administra-
tion [113]. It also established the standard operating 
procedures for ECT use in the clinic i.e., a series of 
eight electric pulses (EPs) of 100 μs and appropriate 
field amplitude must be delivered using either inva-
sive (EPs of 1000  V/cm) or non-invasive electrodes 
(EPs of 1300  V/cm), depending on the depth and 
on the size of the nodules to treat. Recently, in addi-
tion to treating cutaneous and subcutaneous tumors 
the treatment of deep-seated tumors was applied in 
clinical trials. Clinical trials are also ongoing for bone 
metastases, liver metastases, brain tumors, pancreas, 
colorectal cancers (endoscopic electrodes), as dem-
onstrated in number of published reports.
2. Electroporation to transfer nucleic acids inside the 
cells, the electroporation-based gene transfer, consti-
tutes a subcategory of gene therapy. Electroporation 
mediated gene therapy, namely, electrogenetherapy 
(EGT), is an approach rapidly expanding in cancer 
and non-cancer therapeutic domains. Gene electro-
transfer can be achieved by first permeabilizing the 
cell membrane thanks to short and intense electric 
pulse deliveries and second by driving electrophoreti-
cally the DNA toward the electroporated membrane 
thanks to one or several long and low-voltage elec-
tric pulses. It is expected that a protein of interest is 
produced and epitope presentation occurs on MHC 
molecules.
 DNA vaccination consists of the administration 
of a DNA encoding a cancer antigen of interest. 
Encoded antigen will be responsible for the genera-
tion of a pool of specific B and T cells, from which 
some will remain as memory cells for long-term 
protection. Tumor-specific CD8+ T cell generation, 
associated with the secretion of Th1 cytokines (e.g., 
tumor necrosis factor alpha, TNFα and IFNγ) was 
demonstrated. Gene electrotransfer is one of the 
most efficient non-viral techniques and has proven 
its efficiency in many tissues, should they be superfi-
cial (e.g., skin) or internal (e.g., liver and muscle). The 
main limit to the use of gene electrotransfer is related 
to its application to not easily accessible organs. 
The two most advanced EGT strategies are related 
to immunotherapy, namely, DNA vaccination and 
cytokine-based anti-cancer therapies. Intratumoral 
administration of an IL-12-encoding plasmid in con-
junction with EPs demonstrated local and systemic 
anti-tumor effects and improved cure rates of tumors 
in animal models as well as in patients.
3. Irreversible electroporation (IRE) consists in the use 
of excessive electroporation to cause cell death. Dif-
ferent approaches can lead to this outcome including 
the use of very long or very intense electric pulses. 
This local ablative treatment is not selective against 
the tumor cells, killing also the normal cells in the 
volume of tissue exposed to the EP [114].
4. There is also an interest in the combination of anti-
tumor ECT with immunotherapy for long-term and 
systemic anti-tumor responses. Intratumoral recruit-
ment of dendritic cells (DCs) expressing CD80/
CD86 maturation markers, circulating monocytes 
and splenic T lymphocytes was observed after ECT 
treatment in animal model. These studies high-
light immune system activation after the treatment. 
Recently, the mechanisms underlying this immune 
activation were identified. ECT induces an immuno-
genic cancer cell death (ICD) through the liberation 
of ATP and HMGB1 and the translocation of cal-
reticulin to the cell surface. Immunogenic cell death 
is responsible for the generation of tumor-specific T 
cells [113, 114], that are able to kill non-ECT-sensi-
tive cancer cells within the primary tumor. Interest-
ingly, cancer stem cells, thought to be responsible for 
cancer recurrence and metastasis, seem sensitive to 
both extracellular ATP and T cell recognition. These 
tumor-specific T cells can also target metastatic nod-
ules, although there is a lack of direct evidence in the 
absence of a complementary immune stimulation. 
Immunotherapy agents (e.g., cytokines, therapeutic 
antibodies, immune checkpoint blockers, and genes) 
mount immune responses that are synergistic with 
the one triggered by ECT. Overall, this ECT-driven 
immune activation might be responsible for control-
ling local relapses and metastatic spread.
 Antigen presenting cells (APCs), mostly DCs, are of 
great importance for the outcome of vaccination as 
they ensure effective T cell priming and maintenance. 
Therefore, EPs appear to play a pivotal role in anti-
cancer DNA vaccination, not only by enhancing the 
transgene expression but also by recruiting APCs in 
the electroporated tissues: in  vivo electroporation 
can also serve as an adjuvant for DNA vaccination 
[115]. ECT is more efficient in immunocompetent 
mice as compared with immunodeficient animals 
[114, 116]. It has been applied in humans as mono-
therapy and in combination approaches [117–119]. 
Recently Mozzillo et  al. reported that the combina-
tion of ipilimumab and ECT may be beneficial for the 
treatment of metastatic melanoma [118]. The study 
reports that the volume of distant non-ECT-treated 
tumors decreased or was stabilized in 9 patients out 
of 15, possibly through ipilimumab-induced Tregs 
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depletion. Local ECT treatment of cutaneous lesions 
of melanoma was followed by ipilimumab admin-
istration resulting in the complete regression of all 
the cutaneous and visceral metastases for at least 
1  year. Interestingly, vitiligo-like lesions developed 
exclusively around the sites of previous ECT, suggest-
ing that a prior ECT-driven immune activation was 
enhanced by ipilimumab [120]. Electrochemotherapy 
in combination with ipilimumab or pembrolizumab 
or nivolumab was also studied [119]. Combination 
of ECT with immunotherapy is likely to transform 
the ECT from a local to systemic therapy [121]. ECT 
has numerous advantages such as: no side effects; 
is not immunosuppressive; stimulates the immune 
system; rarely causes bleeding even after needles 
insertion; possess anti-hemorrhagic effects; high 
specificity against tumor cells; treatment planning 
procedures are available; standardized equipment 
is available; has reasonable cost; is efficient and fast; 
and requires minimal post treatment care. In conclu-
sion, ETC-based strategies represent highly promis-
ing approaches to induce anticancer systemic effects 
and benefit for patients.
HLA class I antigen processing machinery defects 
in malignant cells in the era of immunotherapy 
of malignant diseases with immune check point inhibitors
The results of a growing number of clinical trials in large 
populations of patients with many types of malignan-
cies have convincingly shown that immunotherapy with 
checkpoint inhibitors as monotherapy or in combina-
tion with other agents including immunomodulators 
can induce long lasting clinical responses in patients 
with malignant diseases. However, these therapeu-
tic effects occur only in a small number of the treated 
patients with a given type of cancer. Furthermore, the 
frequency of responses is markedly different among the 
various types of cancer. Several lines of evidence includ-
ing the increased lymphocyte infiltration in tumors, the 
correlation between mutation load in tumors and clini-
cal outcome in patients treated with immune checkpoint 
inhibitors are consistent with the possibility that clinical 
responses reflect the recognition and elimination of can-
cer cells by cognate T cells unleashed by immune check 
point inhibitors. The interactions between tumor cells 
and cognate T cells are mediated by HLA class I-tumor 
antigen derived peptide complexes. Their synthesis and 
expression require a fully functional HLA class I antigen 
processing machinery (APM). Specifically, proteasome 
isoforms and their active subunits degrade down mostly, 
although not exclusively, endogenous proteins to pep-
tides with the correct length and sequence for HLA class 
I binding. Proteasomal degradation products are shuffled 
by the heterodimeric transporter associated with antigen 
processing (TAP) complex into the lumen of the endo-
plasmic reticulum for loading of beta2 microglobulin 
(β2m)-associated HLA class I α and β chain dimers with 
the help of the chaperone molecules ERp57, calnexin, cal-
reticulin and tapasin. The resulting trimers then travel to 
the plasma membrane and tumor antigen derived pep-
tides are presented to cognate T cells.
The role played by HLA class I APM in the response 
to therapy with immune checkpoint inhibitors has rekin-
dled interest in the characterization of the defects in 
HLA class I APM component expression and/or function 
in malignant cells, since these defects may represent one 
of the mechanisms underlying the resistance to immune 
checkpoint inhibitor-based therapy. Extensive review 
of the literature describing HLA class I APM compo-
nent expression in many types of solid tumors showed 
that these defects are present in all types of solid tumors 
tested with a frequency of at least 40%; in some cancer 
types the frequency of HLA class I APM defects can be 
as high as 75% [122]. These defects have functional rel-
evance, since they cause resistance of cancer cells to cog-
nate T cells’ recognition and lysis [123] and have clinical 
relevance in at least some cancer types [122]. In most 
cases HLA class I APM component downregulation or 
loss is associated with poor clinical course of the disease. 
This association has been suggested to reflect the escape 
of malignant cells from immune surveillance. Defective 
HLA class I-tumor antigen derived peptide processing, 
HLA synthesis and complex assembly can cause abnor-
malities in expression of HLA class I APM components 
and/or function. As a result, the malignant cell recogni-
tion by cognate T cells is defective. Furthermore, in a lim-
ited number of patients (mostly melanoma) who respond 
to T cell-based immunotherapy, disease recurrence was 
associated with HLA class I APM component down reg-
ulation/loss [124]. However, in a few cancer types high 
expression of HLA class I has been found to be associ-
ated with poor prognosis [122]. This unexpected associa-
tion has been suggested to reflect more important role 
of NK cells than that of T cells in the control of tumor 
growth in these malignancies. High HLA class I expres-
sion by tumor cells can inhibit the anti-tumor activity of 
NK cells due to interaction of killer inhibitory receptors 
(KIR) on NK cells with HLA class I that is a KIR-ligands.
Different types of HLA class I defects have been identi-
fied in malignant cells:
1. Total HLA class I antigen loss to selective loss of the 
HLA class I allospecificities encoded in the genome 
of a tumor bearing patient. The latter include loss of 
the gene products of one or two HLA class I loci or 
of the HLA class I allospecificities encoded by the 
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genes present in the major histocompatibility com-
plex region of one of the parental chromosomes 6.
2. Down-regulation represents the most frequent type 
of abnormality in APM components, as complete 
lack of expression has been described only for a few 
APM components such as TAP1 and tapasin, and for 
each of them in a few cases. Since expression of the 
HLA class complex components is determined by the 
co-dominance of the two HLA genes (one of pater-
nal and the other one of maternal origin) as well as 
β2m, multiple factors may contribute to the level of 
the HLA I complex expression.
3. Structural mutations of the genes encoding HLA 
class I APM components have been found at most 
in 5% of the cases. Structural abnormalities in β2m 
which caused lack of HLA class I antigen expression 
by tumor cells have been reported to be associated 
with resistance to immune checkpoint inhibitors. 
A patient with advanced melanoma who acquired 
resistance to the anti-PD-1 antibody, pembroli-
zumab, harbored a homozygous β2m truncating 
mutation [125]. In addition, β2m alterations have also 
been described in two brain metastases from patients 
with mismatch repair deficient colorectal cancer who 
were resistant to immune check point-based therapy 
[126].
4. Epigenetic mechanisms appear to be the most fre-
quent cause of defects in HLA class I APM compo-
nent expression [122]. They include histone acety-
lation defects and methylation of the promoters of 
the genes encoding HLA class I APM components. 
Strategies to counteract the epigenetic mechanisms 
have been developed. They include the use of his-
tone acetylation inhibitors and demethylating agents. 
These approaches have been shown to restore HLA 
class I APM component expression and/or function 
in  vitro, in animal model systems and/or in clinical 
settings. These results emphasize the need to char-
acterize the expression and function of HLA class I 
APM in tumors from patients who are resistant or 
acquire resistance to immune checkpoint inhibitor 
therapy. The resulting information may contribute 
to the successful design of therapies which combine 
immune checkpoint inhibitors with strategies which 
restore the expression and/or function of HLA class 
I APM components. This combinatorial therapy is 
expected to restore patients’ sensitivity to immune 
checkpoint inhibitor therapy at least in some cases 
and to enhance the efficacy of this type of therapy in 
others.
Despite the potential role of HLA class I APM in the 
response to therapy with checkpoint inhibitors, only 
a limited number of studies has correlated the expres-
sion of HLA class I APM components in tumors with 
response to immune checkpoint inhibitor therapy or has 
analyzed the expression of HLA class I APM compo-
nents in tumors from patients who have not responded 
to this type of therapy or have acquired resistance to it. 
However, studies begin to analyze the role of interactions 
between HLA class I antigens and checkpoint molecules 
in the clinical course of the disease. High HLA class I 
antigen expression in intrahepatic cholangiocarcinoma 
and in esophageal cancer has been found to be associated 
with good prognosis only when PD-L1 is not detected 
on tumor cells [127, 128]. One might argue that when 
PD-L1 binds to PD-1 on cognate T cells and inhibits 
their anti-tumor activity, HLA class I antigen expression 
may not play a major role in the interactions of tumor 
cells with cognate T cells. In contrast, when PD-L1 is 
not expressed on tumor cells and cognate T cells are able 
to attack tumor cells, HLA class I antigen expression is 
necessary to recognize and kill malignant cells. The lat-
ter scenario is likely to mimic what happens in the clini-
cal setting when the PD-1/PD-L1 axis is disrupted with 
inhibitors. These findings imply that selection of patients 
to be treated with immune checkpoint inhibitors should 
consider the expression of HLA class I APM components 
by the tumor cells. When this machinery is not fully 
functional, HLA class I independent immunotherapeutic 
strategies appear to be the strategies of choice.
A word of caution about the absolute requirement of 
a fully functional HLA class I APM in tumor cells for 
response to anti-PD-1 therapy. About 70% of patients 
with Hodgkin disease carry β2m-inactivating mutations 
in their tumor cells, which cause lack of HLA class I 
expression [129]. Nevertheless, these patients show dra-
matic response rates to anti-PD-1 therapy [130]. Whether 
this surprising result reflects the targeting of HLA class II 
antigen bearing tumor cells by CD4 cells remains to be 
determined.
Prognostic and predictive markers for patients treated 
with CTLA‑4 and PD‑1 inhibitors
Recently it was demonstrated that patients who dis-
continue nivolumab in combination with ipilimumab 
due to drug toxicity derive an OS benefit similar to that 
observed in the overall population at 18-month follow-up 
[131]. Different diagnostic tests have been approved to 
determine PD-L1 expression in tumor, with different cut-
off positivity. Response by PD-L1 expression level (5%) in 
Checkmate067 showed that patients with PD-L1 positive 
tumors treated with nivolumab in combination with ipili-
mumab had higher ORR [132].
A recent study evaluated the expression of PD-L1 in 
immunotherapy-naïve metastatic melanoma patients and 
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demonstrated that PD-L1 expression was frequently dis-
cordant between primary tumors and metastases as well 
as between intrapatient metastases [133]. A positive uni-
variate association between PD-L1 expression in locore-
gional metastases and melanoma-specific survival was 
observed, but not for primary melanoma. In locoregional 
lymph node metastasis, PD-L1+/TIL+ patients had the 
best outcome, and PD-L1+/TIL− patients had poor out-
come [133].
Studies of survival rate and PD-L1 expression in the 
CheckMate 066 trial demonstrated that, patients treated 
with nivolumab had improved overall survival regard-
less of PD-L1 status, as compared with dacarbazine-
treated patients however the median overall survival 
was not reached in either PD-L1 subgroup treated with 
nivolumab. In the dacarbazine group, the median overall 
survival was slightly longer in the subgroup with positive 
PD-L1 as compared with the subgroup with negative or 
indeterminate PD-L1 status.
The assessment of biomarkers associated with clinical 
outcome following ipilimumab treatment in advanced 
melanoma patients showed that low Serum Lactate 
Dehydrogenase (LDH), absolute monocyte counts 
(AMC), and MDSCs as well as high absolute eosinophil 
counts (AEC), Tregs, and relative lymphocyte counts 
(RLC) is associated with favorable outcome following 
ipilimumab [134]. Patients (43.5%) presenting with the 
best biomarker signature (a baseline signature of low 
LDH, AMC, and MDSCs as well as high AEC, Tregs, and 
RLC) had a 30% response rate and median survival of 
16 months. In contrast, patients with the worst biomark-
ers (27.5%) had only a 3% response rate and median sur-
vival of 4 months [135].
The impact of γδ T-cells on OS and of the first dose of 
ipilimumab in melanoma patients was assessed in 109 
melanoma patients 109 healthy controls [136]. Patients 
with higher frequencies of Vδ1+ cells (≥  30%) had 
poorer OS (p = 0.043). In contrast, higher frequencies of 
Vδ2+ cells (≥ 39%) were associated with longer survival 
(p  =  0.031) independent of the M category or lactate 
dehydrogenase level. Besides, frequencies of both Vδ1+ 
and Vδ2+ cells demonstrated to be candidate biomarkers 
for outcome in melanoma patients following ipilimumab 
[136].
Changes in blood counts and frequency of circulating 
immune cell populations analyzed by flow cytometry 
were investigated in 82 patients to compare baseline val-
ues with different time-points after starting ipilimumab. 
Endpoints were OS and best clinical responses [134]. 
ALC increases at 2–8  weeks (p  =  0.003) and CD4+ 
and CD8+ T cells 8–14 weeks (p = 0.001 and p = 0.02) 
after the first dose of ipilimumab were correlated with 
improved survival and with clinical responses (all 
p  <  0.05). Early increase of ALC and delayed increase 
of CD4+ T cells and early increase of ALC and delayed 
increase of CD4+ and CD8+ T cells were also significant 
[134].
LDH, routine blood count parameters, and clinical 
endpoints OS and best overall response following pem-
brolizumab treatment were investigated in 616 patients 
[137]. The biomarkers studied for pembrolizumab, by 
multivariate model with Cox regression analysis for 
overall survival, were the pattern of visceral metastases; 
serum levels of LDH; relative lymphocyte count; and rel-
ative eosinophil count. Biomarkers showed independent 
positive correlation (all p < 0.001), that was subsequently 
confirmed in the validation cohort (n = 257; all p < 0.01). 
The probability to survive 12 months after the first dose 
was 15% in patients with none out of four favorable fac-
tors, in contrast to 84% for patients with all four favora-
ble factors present. Because of the large differences in 
outcome according to the number of favorable factors, it 
remains unclear whether the combination model is pre-
dictive of pembrolizumab treatment benefit [137].
Table  3 summarizes the prognostic and predictive 
markers for checkpoint inhibitors.
The presence of circulating T cells responding to 
Melan-A or NY-ESO-1 had strong independent prognos-
tic impact on survival in advanced melanoma, suggesting 
that these could be targets for immunotherapy [138]. In 
cohort A patients (84 patients with follow-up after analy-
sis), the presence of T cells responding to peptides from 
NY-ESO-1, Melan-A, or MAGE-3 and the M category 
were significantly associated with survival. NY-ESO-1 
and Melan-A (hazard ratios, 0.29 and 0.18, respectively) 
remained independent prognostic factors in Cox regres-
sion analysis and were superior to the M category in 
predicting outcome [138]. Median survival of patients pos-
sessing T cells responding to NY-ESO-1, Melan-A, or both 
was 21  months, compared with 6  months for all others. 
Melan-A responses were found in 42 and 47% of patients 
in cohort A and B (24  months survival after first occur-
rence of distant metastases; cohort B), respectively. In 
Table 3 Biomarkers for checkpoint inhibitors: prognostic 
(in italics) and predictive details
Ipilimumab Pembrolizumab
Lactate dehydrogenase Stage III-IVB/IVC
Relative lymphocyte counts (RLC) Lactate dehydrogenase (LDH)
Absolute eosinophil counts (AEC) Relative lymphocyte counts (RLC)
Absolute monocyte counts (AMC) Relative eosinophil counts (REC)
Tregs: unknown
MDSC: unknown
γδ T-cells: uncertain
Increase CD4+ CD8+ T cell: uncertain
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contrast, the proportion was only 22% for NY-ESO-1 and 
23% for Melan-A in those who died within 6 months [138].
Identifying peptides recognized by individual T cells 
is important for understanding and treating immune-
related responses. A peptide–Major Histocompatibility 
Complex (MHC) multimers labeled with individual DNA 
barcodes to screen > 1000 peptide specificities in a sin-
gle sample that detect low-frequency CD8 T cells specific 
for virus- or cancer-restricted antigens was investigated 
[139]. Several neoepitope-specific T cells in tumor-infil-
trating lymphocytes were identified. Barcode-labeled 
pMHC multimers enable the combination of functional 
T-cell analysis with large-scale epitope recognition profil-
ing to characterize T-cell recognition in various diseases, 
including in clinical patients samples [139].
In conclusion, prognostic and predictive markers for 
patients treated with CTLA-4 and PD-1 inhibitors are:
1. Clinical outcome of first shot which may be the most 
relevant biomarker.
2. Established prognostic markers like tumor-stage and 
LDH which are valid in checkpoint inhibitor therapy.
3. Lymphocyte and eosinophil counts which may have 
predictive value.
4. Preexisting functional antitumor T cell responses 
which should be better analyzed.
Update on PD‑L1 and related markers
FDA approvals for immune checkpoint blockade agents 
have been numerous both in melanoma and other 
tumors. A number of these approvals have been accom-
panied by immunohistochemical (IHC) assays for PD-L1 
in the form of complementary or companion diagnostics 
(CDxs).
Complementary diagnostic for melanoma was 
approved approximately 5  years after anti-CTLA-4 was 
first approved, and as such, practitioners were well-
accustomed to administering checkpoint blocking agents 
to patients with melanoma without testing for PD-L1 
expression. This is in contrast with non-small cell lung 
carcinoma, where approvals for the agent itself were 
often accompanied by approval for the Companion or 
Complementary diagnostic.
The publicly available data on PD-L1 IHC testing in 
patients with metastatic melanoma as of October 2015, 
shows that practitioners tested approximately 37% of 
their patients for PD-L1 expression vs. testing 98% of 
patients for BRAF mutations (Source: BrandImpact/
BrandImpact Dx). When melanoma patients were tested, 
only 20% of surgical pathology labs were running CDxs, 
with more labs either running a laboratory developed 
tests (LDT) for PD-L1 IHC or sending the test out to be 
performed by a Reference Laboratory. Since the PD-L1 
IHC Complementary Dx for melanoma was approved by 
FDA after this survey was conducted, it is possible that 
the proportion of oncologists ordering PD-L1 testing as 
well as surgical pathology labs performing the test will 
increase in subsequent surveys.
There are numerous commercially available PD-L1 
immunohistochemistry (IHC) assays (Table  4). It is 
impractical for most surgical pathology laboratories to 
host four different IHC assays for PD-L1, thus there is 
great interest in understanding the comparative perfor-
mance of these assays.
To that aim, the Blueprint PD-L1 IHC Assay Com-
parison Project was initiated. It is an industrial-academic 
collaborative partnership to provide information on the 
analytical performance of these four PD-L1 IHC assays 
[140]. Phase 1 was conducted by staining n = 40 NSCLC 
with each of the four PD-L1 IHC assays (using clones 
22C3, 28-8, SP142, and SP263). Both the percent of tumor 
cells and immune cells staining for PD-L1 were assessed 
by three pathologists, and their scores were averaged. 
Three of the four assays (22C3, 28-8, and SP263) were 
closely aligned on tumor cell staining whereas the fourth 
(SP142) showed consistently fewer tumor cells stained. 
Table 4 Commercially available PD-L1 IHC assays
The scoring systems noted below often depend on the line of therapy and the tumor type being tested. An increasing number of assays from different companies are 
reaching the market
BMS Merck Roche Astra Zeneca
mAb clone 28-8 22C3 SP142 SP263
Automated Yes Yes Yes Yes
Diagnostic partner Dako Dako Ventana Ventana
Machine Link 48 Link 48 Benchmark ULTRA Benchmark ULTRA
Scoring Tumor cells (membrane) Tumor cells (membrane) Tumor cells/or immune (membrane) Tumor cells (membrane)
Positive cutoff ≥ 5% (also studied ≥ 1% and ≥ 10% 
thresholds
≥ 1% for trial enrollment
Other analysis at > 50%
TC3 (> 50%) or IC3 (> 10%)
TC2/3 or IC2/3 (> 5%)
TC 1/2/3 or IC 1/2/3 (> 1%)
TC0 and IC0 (0%)
≥ 25%
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All the assays demonstrated immune cell staining, but 
with greater variability than with tumor cell staining.
A second study tested 90 archival NSCLCs stained by 
different PD-L1 IHC assays and scored by 13 patholo-
gists. The assays tested in this second study included: (1) 
28-8 assay on Dako Link 48; (2) 22c3 assay on Dako Link 
48; (3) SP142 assay on Ventana Benchmark (LDT mim-
icking the IUO test); and (4) E1L3N antibody on Leica 
Bond (LDT). Similar to the Blueprint study, the assay 
using the SP142 antibody was an outlier detecting sig-
nificantly less tumor cell PD-L1 expression. It was also 
an outlier with respect to detecting immune cell PD-L1 
expression [141].
To determine whether the performance characteris-
tics of the SP142 assays were due to the SP142 antibody 
itself or to the assay conditions, we conducted a study 
where we held all of the other assay conditions (antigen 
retrieval, buffers, amplification systems) essentially con-
stant and changed only the antibody. In this study, we 
assessed archival melanoma cases, and compared the 
5H1, SP142, SP263, 22C3, and 28-8 antibody clones. We 
found that all antibodies could demonstrate similar stain-
ing properties regarding labeling PD-L1 display by both 
tumor cells and immune cells, if all other assay conditions 
were constant. These findings indicate that it is likely the 
assay conditions (beyond the primary antibody itself ) 
that contribute to the differences observed between the 
SP142 assay and the other studied assays [142].
In addition to PD-L1, there is a number of other can-
didate biomarkers which have been nominated, includ-
ing PD-1, CD8, and mutational load. PD-L2 has not been 
well-studied yet, due to the lack of well-validated com-
mercially available antibodies. We next used the TCGA 
dataset to assess how these different markers related to 
PD-L1 expression. We found that PD-L1, PD-L2, PD-1, 
cytolytic activity (CYT), and mutational load are all posi-
tive prognostic features in patients with melanoma. Nota-
bly, PD-L1, PD-L2, PD-1 and CYT are all closely linked to 
each other and to Th1/IFNγ expression in patients with 
melanoma, while mutational load is not. When principal 
component analysis was conducted on these five vari-
ables, PD-L1, PD-L2, PD-1 and CYT all formed the first 
principal component, with each contributing near equally, 
while mutational load was orthogonal and formed the 
second principle component. We then assessed the rela-
tive contribution of these factors to survival using condi-
tional inference modeling, which revealed that PD-1/CYT 
expression (i.e., an inflamed tumor microenvironment) as 
the most impactful feature, followed by mutational den-
sity in tumors that were less inflamed [143].
Additional studies are underway to perform similar 
analyses as they relate to predicting response or resist-
ance to checkpoint blockade, as well as further refining 
prognostic algorithms. While genomic studies and gene 
signatures contribute global assessments of the tumor 
microenvironment, emerging data reinforces the con-
tribution of spatially-resolved approaches to protein 
expression. Future biomarker panels for patients with 
melanoma will likely include multiplex IHC/immuno-
fluorescent studies as well as genomic studies and gene 
signatures. Assay development will thus require the inte-
gration and prioritization of these different modalities.
Understanding responses to cancer therapy: lessons 
learned from mouse and man
The Cancer Genome Atlas (TCGA) program per-
formed a systematic multi-platform characterization of 
333 cutaneous melanomas at the DNA, RNA, and pro-
tein levels to create a catalog of somatic alterations and 
describe their potential biological and clinical signifi-
cance. TCGA represents the largest integrative analysis 
of cutaneous melanoma; it establishes a framework for 
melanoma genomic classification (BRAF, RAS, NF1, and 
Triple-WT), it identifies additional subtypes that may 
benefit from MAPK-and RTK-targeted therapies and 
multi-dimensional analyses identify immune signatures 
associated with improved survival [144].
Therapeutic targeting of oncogenic BRAF mutations 
results in rapid regression of melanoma tumors in most 
patients. Clinical trials showed that treatment with BRAF 
inhibitors resulted in a survival benefit over then stand-
ard of care therapy with dacarbazine substantiating the 
FDA approval of the first of these agents (vemurafenib) in 
2011. However, most of patients progressing on therapy 
within 6  months that is the limitations of this therapy. 
Insight into resistance mechanisms has led to advances in 
therapy, including the use of combined BRAF and MEK 
inhibition, which was shown to improve progression free 
survival in patients; even with the combination, most of 
patients progress within a year. There is a critical need to 
identify pre-treatment biomarkers of response and resist-
ance, as well as early on-treatment markers of resistance 
which are potentially actionable.
Substantial research efforts internationally focused on 
response and resistance to targeted therapy for mela-
noma in biopsies of patients treated with BRAF inhibi-
tors. The team of researchers at the MD Anderson CC 
performed genomic analysis in pre-treatment and pro-
gressing lesions, with immune profiling in pre-treatment, 
on-treatment and progressing lesions. Through such 
studies, multiple genomic mechanisms of resistance have 
been identified and published.
Although oncogenic mutations contribute to tumor 
escape via multiple mechanisms, including through 
immune evasion mutations can make tumors more 
immunogenic. Therefore, in addition to studying 
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genomic mechanisms of resistance, immune profiling 
was also performed in tumors over the course of therapy 
to gain insights into anti-tumor immunity was researched 
out. Specifically, T cell infiltrate and markers of cytotox-
icity, the expression of immunosuppressive cytokines and 
VEGF as well as PD-1 and PD-L1 were assessed. Through 
these studies, immune mechanisms of response and 
resistance to targeted therapy were also identified. Treat-
ment with BRAF-targeted therapy increased melanoma 
antigens expression (e.g., MART) and CD8+ T cells 
infiltrate resulting in more favorable TME. Furthermore, 
decreased the level of immunosuppressive cytokines and 
VEGF, within 2 weeks of starting therapy providing sup-
port for potential synergy of BRAF-targeted therapy and 
immunotherapy [69]. However along with these favorable 
changes, an increase in expression of the immunomodu-
latory molecule PD-L1 early during treatment was noted, 
suggesting a possible immune mechanism of resistance to 
therapy. Interestingly, these favorable immune effects are 
not likely to be solely related to increased melanoma anti-
gens but to overall changes in the tumor microenviron-
ment. Hypothesis that combining targeted therapy and 
immune checkpoint blockade would enhance responses 
to therapy was tested in mouse models. A synergy was 
found in these studies, with delayed tumor outgrowth 
and prolonged survival when mice were treated with 
BRAF targeted therapy and PD-1 blockade, compared 
to either therapy alone [70]. There was a modest CD8 
T cell infiltrate in the setting of BRAF inhibitor mono-
therapy, but when PD-1 blockade was added to a back-
bone of a targeted therapy a dramatic increase in CD8 T 
cell infiltrate in the tumors was observed [70]. Based on 
this observation, multiple trials are underway combining 
these strategies for melanoma as well as other cancer.
In addition, these treatments are also being assessed 
in patients with earlier stage disease. Upfront surgery is 
the standard treatment for patients with clinical stage 
III melanoma. However, most patients treated with 
upfront surgery will relapse and die (~ 70%). A phase 2 
clinical trial to test the hypothesis that treatment with 
neoadjuvant and adjuvant BRAF/MEK inhibitors would 
improve RFS in patients with bulky stage III melanoma 
and a BRAF mutation (vs upfront surgery and standard of 
care adjuvant therapy) is currently underway, and trans-
lational assessments to identify molecular and immune 
determinants of response are ongoing [145].
Furthermore, mechanisms of responses to immune 
checkpoint blockade targeting CTLA-4 and PD-1 
through translational research in human samples are also 
studied. Not all patients respond to immune checkpoint 
inhibitor therapy particularly as monotherapy. Tremen-
dous efforts are underway to identify predictive biomark-
ers of response to immune checkpoint blockade based 
in tumor biopsies including mutational load at baseline 
with evidence that patients with a higher mutational load 
have improved responses to checkpoint inhibitor therapy 
[47] though this is not perfectly predictive and better bio-
markers are needed. In addition, immune markers are 
being studied including CD8 T cell density and distribu-
tion as well as IFNγ response gene signatures [96, 97].
Cohort of patients with metastatic melanoma who 
initially received Ipilimumab and then went onto PD-1 
blockade therapy, and isolated tissue samples from mul-
tiple time points on therapy and embarked on a deep 
molecular and immune profiling of these tumors was 
carried out [146]. In this study, immune signatures in 
pre-treatment tumor biopsies assessed by a 12-marker 
immunohistochemistry panel largely failed to predict 
response to PD-1 blockade, but signatures in on-treat-
ment biopsies were highly predictive [146]. Gene expres-
sion profiling using Custom 795 gene NanoString set was 
used to see if responses to immune checkpoint blockade 
can be predicted via gene expression profiling. Gene 
expression profiles at pre-treatment time point largely 
failed to predict response to immune checkpoint block-
ade. However, signatures in on-treatment PD-1 samples 
were strongly predictive [146].
These data suggest that clinically useful biomarkers for 
response to immune checkpoint blockade exist, but spe-
cific time point to assess them might be critical. The study 
needs to be validated in additional cohorts, the emphasis, 
should rather be on assessing adaptive immune responses 
in early on-treatment samples for response to checkpoint 
therapy (and should be incorporating this into clinical 
trials) instead on pre-treatment biomarkers. Importantly, 
we are also bringing immune checkpoint inhibitor treat-
ment to patients with earlier stage disease, and have an 
ongoing phase 2 trial to test the hypothesis that treat-
ment with neoadjuvant (+ adjuvant) immune checkpoint 
inhibitors will be associated with a high pathological 
complete response (path CR) rate and immune infiltrate 
(NCT02519322). In this trial, patients with stage IIIB or 
stage IIIC melanoma are randomized to treatment with 
PD-1 monotherapy versus combined CTLA-4 and PD-1 
blockade. Preliminary findings are available [147] though 
mature data will not be available for some time.
In addition to the influence of the tumor and micro-
environment in modulating responses to therapy in 
melanoma and other cancers, there is a growing role of 
environmental factors that may contribute to therapeu-
tic response and resistance. Pioneering work by Gajew-
ski and Zitvogel demonstrated that bacteria in the gut 
could modulate therapeutic responses to immune check-
point blockade in pre-clinical models [107, 148]. We 
recently studied this in a cohort of patients with meta-
static melanoma, and found that differential bacterial 
Page 27 of 31Ascierto et al. J Transl Med  (2017) 15:236 
signatures existed in responders versus non-responders 
to immune checkpoint blockade (specifically anti-PD-1 
therapy), and reported these findings at the annual meet-
ing of the American Society of Clinical Oncology in 
2017. Additional studies are currently underway to better 
understand the mechanism behind this, and to develop 
strategies to enhance therapeutic responses via modula-
tion of the microbiome.
Another innovative technique is the use of Raman 
spectroscopy, a noninvasive and label-free optical tech-
nique that provides detailed information about the 
molecular composition of a sample. It can potentially 
predict skin toxicity due to tyrosine kinase inhibitors 
treatment. Raman spectra of skin of patients undergoing 
treatment with MEK, EGFR, or BRAF inhibitors, which 
are known to induce severe skin toxicity were collected 
(three patients were included for each inhibitor) [149]. 
The algorithm, based on partial least squares-discrimi-
nant analysis (PLS-DA) and cross-validation by boot-
strapping, can identify patients with risk for cutaneous 
adverse events. For MEK and EGFR inhibitors, discrimi-
native power was more than 90% in the viable epidermis 
skin layer; whereas for BRAF inhibitors, discriminative 
power was 71% [149]. Raman spectroscopy can detect 
skin toxicity induced by TKI treatment on locations not 
affected from a dermatological and histological point-
of-view. It has better discriminative power in the case of 
MEK and EGFR inhibitors which are known to be associ-
ated with inhibition of MAPK pathway on healthy tissue 
contrary to BRAF inhibitors. There is good correlation 
(> 80%) of Raman signature of the skin and drug concen-
tration into the blood in the case of EGFR inhibitors and 
VE skin layer.
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